Biocidal composition

Abstract

The present invention relates to compositions containing the following ingredients: (a) 25% to 43% by weight of 5-isopropyl-2-methylphenol (carvacrol); (b) 20% to 38% by weight of 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol); and (c) 21% to 38% by weight of 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol). The total of the ingredients can be up to 100% by weight. These compositions have potent biocidal activity. The present invention also relates to products containing these compositions and methods of using them.

Description

[Technical Field]

[0001] This application claims the benefit of European patent application EP22382760.1, filed on August 4, 2022. The present invention relates to the field of biocidal compounds, in particular compositions with bactericidal, virucidal, fungicidal and yeasticidal activity, and products containing same, as well as their production processes and uses in the pharmaceutical, veterinary, cosmetic, plant health, food and feed industries, hygiene and cleaning industries and perfumery sectors. [Background technology]

[0002] Currently, disinfectants with bactericidal, virucidal, fungicidal, and yeasticidal properties are derived from industrial chemicals. These agents contain quaternary ammonium salts, ethanol, and other elements, which can be environmentally hazardous at high concentrations and are rarely biodegradable. Furthermore, long-term use can lead to resistance and reduced effectiveness. For this reason, alternative antibacterial and virucidal agents of natural origin, including carbohydrates, alcohols, esters, aldehydes, and ketones, have been developed. These essential oils contribute to the biological properties of aromatic and medicinal plants. Many essential oils and their components also possess pharmacological benefits, with proven anti-inflammatory, antioxidant, and anticancer properties. However, the extraction of these essential oils is very expensive, requires large amounts of raw materials, and can have a significant negative impact on the ecosystems from which they are obtained. While the antibacterial and virucidal effects of some essential oil active ingredients have been demonstrated, the minimum amount of active ingredient required to ensure inhibitory activity, i.e., the minimum inhibitory concentration (MIC), is known to be very high (Halldor Thormar, Lipids and Essential Oils as Antimicrobial Agents, Wiley Ed.). This means that the effective biocidal doses of these active ingredients are very high, which not only directly and significantly impacts the manufacturing costs of antibacterial products containing them, but also entails the negative environmental impacts already mentioned. Furthermore, the higher the required dosage of these active ingredients, the greater the likelihood of adverse reactions to them.

[0003] Thus, it follows from the current state of the art that there remains a need to provide effective, safe, stable, and inexpensive compositions that have fast-acting, long-lasting, broad-spectrum biocidal activity and are not harmful to the environment. Summary of the Invention

[0004] The inventors have discovered that the following specific compositions are useful as biocides: 5-isopropyl-2-methylphenol, 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol, and optionally 5-methyl-2-(propan-2-yl)phenol and / or 5-methyl-2-(propan-2-yl)cyclohex-1-ol. Indeed, the compositions of the present invention exhibit enhanced biocidal activity over a broad range. As demonstrated in the experimental section, the compositions of the present invention demonstrate unexpectedly effective bactericidal, fungicidal, virucidal, and yeasticidal activity, even when used at very low concentrations. In fact, this enhanced effect far exceeds the sum of the biocidal effects of each active ingredient (as demonstrated in the examples below), thereby allowing the compositions of the present invention to exhibit synergistic biocidal activity at much lower concentrations than the individual components. This enhanced effect has been demonstrated in the treatment or prevention of infected areas on living tissues, such as skin, mucous membranes, and soft tissues, as well as on non-living materials and surfaces. It is also applicable to the treatment or prevention of spaces and environments for home use and professional activities. In fact, the effectiveness of the compositions of the present invention is greater and more sustained than that of bleach. Furthermore, because the components that make up the compositions of the present invention are non-toxic, the drawbacks associated with the use of bleach are overcome.

[0005] The compositions of the present invention also have the advantage of being versatile and useful for the manufacture of products in various fields, such as pharmaceuticals, veterinary medicine, cosmetics, agriculture or plant health, the hygiene / cleaning industry, and the perfume industry. In fact, the compositions are also useful in the food / feed industry for human or animal consumption, and all active ingredients of the compositions of the present invention can be "food / feed grade." Furthermore, they can be used in very low concentrations, so they do not alter cosmetic formulations or cause side effects such as skin irritation or allergies.

[0006] Furthermore, the compositions of the present invention are stable under manufacturing, storage, and normal use conditions, allowing them to be used in small amounts without losing their biocidal activity. For example, up to 98.7% biocidal efficacy is maintained for 10 days after the initial application of the product. In fact, their long half-life allows for reduced application intervals, significantly reducing costs without sacrificing biocidal efficacy. They also extend the useful life of treated surfaces and objects. The compositions of the present invention are particularly advantageous in the cosmetics, food / feed, and perfume industries, simplifying procedural protocols and reducing application frequency without compromising quality, thereby reducing economic costs. Furthermore, the biocidal efficacy of the compositions of the present invention is maintained over a wide pH range, and they exhibit surprisingly good disinfection efficacy even in misting applications (as demonstrated in the examples below).

[0007] In addition, the compositions of the present invention have been found to exhibit unexpected synergistic effects when combined with other biocidal active ingredients. Experimental data demonstrates that combining the compositions of the present invention with commonly used bactericidal and virucidal active ingredients can synergistically increase their activity and broaden their spectrum of activity. This effect is commonly known as the "biocidal booster effect." Without being bound by theory, this effect is associated with the fact that the compositions of the present invention are effective in preventing pathogens from adhering to surfaces by inhibiting biofilm growth. This means that, in addition to their inherent ability to kill pathogens, the compositions of the present invention are also useful as adjuvants and biocidal boosters for other biocidal active ingredients. As demonstrated in the experimental section, the compositions of the present invention are effective against the most common pathogens (including bacteria, fungi, and yeasts) that cause high rates of illness in humans and animals. This high efficacy and broad spectrum is achieved even with low effective doses of the compositions. Furthermore, the compositions of the present invention are effective against antibiotic-resistant pathogens (e.g., primarily spore-forming Clostridium difficile) and emerging pathogens (e.g., SARS-CoV-2). They are also effective against biofilms formed by pathogenic microorganisms such as Pseudomonas aeruginosa and Acinetobacter baumannii, making them particularly useful in hospital environments where these biofilms and resistant pathogens are of major concern. Finally, the compositions of the present invention have a very low environmental impact, and their use does not adversely affect the ecosystems or organisms from which they are obtained. These combinations do not require rinsing after application in the disinfection process. The inventors conducted extensive research to find the optimal combination of active ingredients that act synergistically while maintaining a low toxicity profile.

[0008] Thus, a first aspect of the present invention relates to a composition comprising: 5-isopropyl-2-methylphenol from 0.1% to 45% by weight; 0.1% to 45% by weight of 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane; 0.1% to 60% by weight of 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol; optionally, 0.1% to 45% by weight of 5-methyl-2-(propan-2-yl)phenol; optionally, 0.1% to 45% by weight of 5-methyl-2-(propan-2-yl)cyclohexan-1-ol; optionally, one or more additional active ingredients; and Optionally, one or more suitable and acceptable excipients or carriers; the sum of these ingredients may total up to 100% by weight.

[0009] A second aspect of the present invention relates to an article of manufacture comprising: (i) an effective amount of the composition defined in the first aspect; and (ii) one or more suitable and acceptable excipients or carriers; A third aspect of the invention relates to the use of a composition of the first aspect or a product of the second aspect in the therapeutic (pharmaceutical and veterinary), cosmetic, agricultural, food / feed / nutrition industries, hygiene / cleaning industries, and perfumery industries. Also part of the invention is an inventive process for preparing a composition comprising a composition of the first aspect and a product of the second aspect.

[0010] A third aspect of the present invention relates to the use of a composition as defined in the first aspect or a product as defined in the second aspect in the therapeutic (pharmaceutical and veterinary), cosmetic, agricultural, food / feed / nutrition industries, hygiene / cleaning industries, and perfumery industries.

[0011] Also forming part of the invention is an inventive process for preparing a composition comprising the composition defined in the first aspect and the product defined in the second aspect. [Brief explanation of the drawings]

[0012] [Figure 1] Figure 1 shows the antibacterial activity of Composition 1 (1), containing 1% (by weight) of Inventive Composition Example 22, and Composition 2 (2), containing 2% (by weight) of Inventive Composition Example 22, compared with untreated (C1; negative control) and bleach (C2; positive control) against growing Clostridium difficile cells. Efficacy is shown on the y-axis as the change in optical density at 600 nm (DO600 / 48h - DO600 / 0h) at the indicated times (5, 15, and 30 minutes) for each ribotype 027 of Clostridium difficile. Figure 1. A: Clostridium difficile 027, 5 minutes of exposure; Figure 1. B: Clostridium difficile 027, 15 minutes of exposure; Figure 1. C: Clostridium difficile 027, 30 minutes of exposure. [Figure 2]Figure 2 shows the antibacterial activity of Composition 1 (1), containing 1% (by weight) of Inventive Composition Example 22, and Composition 2 (2), containing 2% (by weight) of Inventive Composition Example 22, compared with untreated (C1; negative control) and bleach (C2; positive control) against growing Clostridium difficile cells. Efficacy is shown on the y-axis as the change in optical density at 600 nm (DO600 / 48h - DO600 / 0h) at the indicated times (5, 15, and 30 minutes) for each ribotype 078 Clostridium difficile. Figure 2. A: Clostridium difficile 078, 5 minutes of exposure; Figure 2. B: Clostridium difficile 078, 15 minutes of exposure; Figure 2. C: Clostridium difficile 078, 30 minutes of exposure.

[0013] All terms used in this application shall be understood to have their ordinary meaning as known in the art unless otherwise specified. More specific definitions of certain terms used in this application are set forth below and are intended to be applied consistently throughout the specification and claims, unless a broader definition is expressly provided.

[0014] For purposes of the present invention, the ranges provided include both the lower and upper limits of the range. Ranges of weight, temperature, time, weight, etc., should be considered approximate unless otherwise specified.

[0015] The terms "weight percent," "weight / weight percent," and "w / w%" have the same meaning and are used interchangeably. They indicate the percentage of each component of a composition relative to the total weight of the composition. For example, 1% by weight corresponds to 1 g in a total weight of 100 g.

[0016] For the purposes of this invention, the term "extract" refers to a concentrated plant preparation obtained by removing active ingredients from a plant using a suitable method. Such active ingredients can be obtained from different parts of the plant using different extraction / distillation techniques. Suitable methods for removing active ingredients include steam entrainment, carbon dioxide (CO2), supercritical fluids, steam distillation, microwaves, and the use of organic solvents. These methods are selected depending on the origin of the plant and the active ingredients contained, and can be carried out at low temperatures or under specific temperature conditions.

[0017] The resulting active ingredients are sometimes directly incorporated into food / feed, pharmaceutical, or cosmetic compositions in various forms, such as pure or semi-pure ingredients, solid or liquid extracts, or solid algal material. Plant extracts contain not only a single ingredient but multiple ingredients, many of which are effective. Extracts containing the active ingredients of the present invention (carvacrol, eucalyptol, terpinen-4-ol, thymol, and / or menthol) can be obtained, for example, from plant extracts selected from the following group: Honeysuckle family extracts (e.g., Eucalyptus extract, Eucalyptus globulus; Melaleuca extract, Melaleuca alternifolia), Lamiaceae extracts (e.g., Mentha spp., Peppermint; Thyme spp., Thymus vulgaris, Thymus capitata; Oregano spp., Oregano vulgare), Rutaceae extracts (e.g., Citrus extract, Citrus reticulata), Cupressaceae extracts (e.g., Inule extract, Inule oxycedrus), Pinaceae extracts (e.g., Pinus sylvestris), and mixtures thereof. For purposes of the invention, the claimed amount corresponds to the pure active ingredient or to the amount of extract containing the claimed amount of pure active ingredient. For purposes of the invention, "essential oil" refers to a highly concentrated and purified extract. Thus, the term "extract" encompasses "essential oil." In the present invention, the active ingredients are desirably isolated or synthetically obtained and used in "pure" form. The ingredients of the present invention are commercially available in pure form from several suppliers.

[0018] As noted above, the composition according to the first aspect of the present invention comprises: (a) 5-Isopropil-2-metilfenol, 0.1% to 45% by weight; (b) 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane, 0.1% to 45% by weight; (c) 0.1% to 60% by weight of 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol; (d) optionally, 0.1% to 45% by weight of 5-Methyl-2-(propan-2-yl)phenol; (e) optionally, 0.1% to 45% by weight of 5-Methyl-2-(propan-2-yl)cyclohexan-1-ol; (f) optionally, one or more additional active ingredients; (g) optionally, one or more suitable and acceptable excipients or carriers; The sum of these ingredients may not exceed 100% by weight.

[0019] In the context of the present invention, the compounds (a) "5-isopropyl-2-methylphenol" and "carvacrol" have the same meaning and are used interchangeably. They refer to the compound having the CAS number 499-75-2, the structure of which is as follows: [ka]

[0020] The compositions of the invention contain 0.1% to 45% by weight of carvacrol. In an embodiment, the compositions of the invention contain 0.5% to 45% by weight of carvacrol. In an embodiment, the compositions of the invention contain 1% to 43% by weight of carvacrol. In an embodiment, the compositions of the invention contain 2% to 43% by weight of carvacrol. In an embodiment, the compositions of the invention contain 3% to 43% by weight of carvacrol. In an embodiment, the compositions of the invention contain 3.5% to 40% by weight of carvacrol. In an embodiment, the compositions of the invention contain 4% to 40% by weight of carvacrol. In an embodiment, the compositions of the invention contain 30% to 40% by weight of carvacrol.

[0021] In one embodiment, the compositions of the present invention contain 15% to 40% carvacrol by weight. In one embodiment, the composition contains 25% to 40% carvacrol by weight. In one embodiment, the composition contains 30% to 40% carvacrol by weight. In one embodiment, the composition contains 35% to 40% carvacrol by weight. In one embodiment, the composition contains 25% to 43% carvacrol by weight. In one embodiment, the composition contains 30% to 40% carvacrol by weight. In one embodiment, the composition contains 30% to 35% carvacrol by weight. In one embodiment, the composition contains 35% to 40% carvacrol by weight. In one embodiment, the compositions of the present invention comprise from 4% to 30% carvacrol by weight. In one embodiment, the composition contains 4% to 20% carvacrol by weight. In one embodiment, the composition contains 4.2% to 15% carvacrol by weight. In one embodiment, the composition contains 4.5% to 10% carvacrol by weight. In one embodiment, the composition contains 3% to 25% carvacrol by weight. In one embodiment, the composition contains 3% to 12% carvacrol by weight. In one embodiment, the composition contains 12% to 25% carvacrol by weight.

[0022] In the context of the present invention, compound (b) "1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane," "1,8-cineole," and "eucalyptol" have the same meaning and are used interchangeably. They refer to the compound having CAS number 470-82-6, the structure of which is as follows: [ka]

[0023] The compositions of the present invention contain from 0.1% to 45% by weight of eucalyptol. In one embodiment, the composition contains 0.5% to 42% eucalyptol by weight. In one embodiment, the composition contains 1% to 40% eucalyptol by weight. In one embodiment, the composition contains 2% to 35% eucalyptol by weight. In one embodiment, the composition contains 3% to 32% eucalyptol by weight. In one embodiment, the composition contains 3.5% to 30% eucalyptol by weight. In one embodiment, the composition contains 4% to 28% eucalyptol by weight.

[0024] Other embodiments include 20% to 38% eucalyptol by weight, 25% to 36% eucalyptol by weight, 31% to 36% eucalyptol by weight, and even 25% to 30% eucalyptol by weight.

[0025] In one embodiment, the compositions of the present invention comprise from 3% to 30% eucalyptol by weight, hi one embodiment, from 3% to 12% eucalyptol by weight. In one embodiment, the composition contains 12% to 30% eucalyptol by weight.

[0026] In the context of the present invention, the compound (c) "4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol" and "terpinen-4-ol" have the same meaning and are used interchangeably. They refer to a compound having the following structure: [ka]

[0027] In the present invention, the term "terpinen-4-ol" encompasses both individual enantiomers (i.e., the R-enantiomer and the S-enantiomer) and "enantiomeric mixtures" comprising them. The term "enantiomeric mixture," as used herein, refers to a mixture of two enantiomers, including a racemic mixture and a mixture enriched in one of the two enantiomers. The term "racemic mixture" or "racemate," as used herein, refers to a mixture containing equal amounts of the R-enantiomer and the S-enantiomer, meaning that the molar ratio of the two enantiomers in a racemic mixture is 50:50. The term "enantiomer-enriched mixture," as used herein, refers to a mixture of enantiomers (the R-enantiomer and the S-enantiomer), meaning that the amount of one enantiomer is greater than the other, and that the molar ratio of the two enantiomers in an enantiomerically enriched mixture is not 50:50. The term "enantiomeric excess (ee)" refers to the difference in the amount of each enantiomer in a mixture as a percentage of the total amount of compound in the mixture (percentage, x 100%). When the R-enantiomer is in excess, the enantiomeric excess is calculated by the following formula: ee % = ([R] - [S]) / ([R] + [S]) x100 When the S-enantiomer is in excess, the enantiomeric excess is calculated using the following formula: ee % = ([S] - [R]) / ([R] + [S]) x100

[0028] The term "enantiomeric purity (ep)" refers to the purity of one enantiomer relative to the other. When the R-enantiomer is in excess, the enantiomeric purity is calculated using the following formula: ep % = ([R] / ([R] + [S]) x100

[0029] When the S-enantiomer is in excess, the enantiomeric purity is calculated using the following formula: ep % = ([S] / ([R] + [S]) x100

[0030] In the above formula, [R] and [S] represent the mole fractions of each enantiomer in the mixture, and [R] + [S] = 1.

[0031] In the present invention, the racemic mixture of terpinen-4-ol refers to the compound with CAS number 562-74-3, the structure of which is as follows: [ka]

[0032] The (S)-enantiomer of terpinen-4-ol refers to the compound with CAS number 2438-10-0, the structure of which is as follows: [ka]

[0033] The (R)-enantiomer of terpinen-4-ol refers to the compound with CAS number 20126-76-5, the structure of which is as follows: [ka]

[0034] The compositions of the present invention contain from 0.1% to 60% by weight of terpinen-4-ol. In one embodiment, the composition contains 10% to 57% terpinen-4-ol by weight. In one embodiment, the composition contains 15% to 55% terpinen-4-ol by weight. In one embodiment, the composition contains 17% to 54% terpinen-4-ol by weight. In one embodiment, the composition contains 20% to 53% terpinen-4-ol by weight. In one embodiment, the composition contains 22% to 52% terpinen-4-ol by weight. In one embodiment, the composition contains 25% to 50% terpinen-4-ol by weight. In one embodiment, the composition contains 21% to 38% terpinen-4-ol by weight. In one embodiment, the composition contains 25% to 36% terpinen-4-ol by weight. In one embodiment, the composition contains 31% to 36% terpinen-4-ol by weight. In one embodiment, the composition contains 25% to 30% terpinen-4-ol by weight.

[0035] In an embodiment, the compositions of the invention comprise 3% to 55% by weight of terpinen-4-ol. In one embodiment, the compositions of the invention contain 3% to 12% by weight of terpinen-4-ol. In some embodiments, the compositions contain 12% to 21% by weight of terpinen-4-ol. In one embodiment, the composition contains 21% to 55% terpinen-4-ol by weight. In one embodiment, the composition contains 45% to 52% terpinen-4-ol by weight.

[0036] In the context of the present invention, the compound (c) "5-methyl-2-(propan-2-yl)phenol" and "thymol" have the same meaning and are used interchangeably. They refer to the compound having the CAS number 89-83-8, the structure of which is as follows: [ka]

[0037] The compositions of the present invention contain from 0.1% to 45% by weight of thymol. In one embodiment, the composition contains 1% to 42% thymol by weight. In one embodiment, the composition contains 1% to 40% thymol by weight. In one embodiment, the composition contains 1.5% to 38% thymol by weight. In one embodiment, the composition contains 2% to 33% thymol by weight. In one embodiment, the composition contains 2% to 32.5% thymol by weight. In one embodiment, the composition contains 3% to 32% thymol by weight. In one embodiment, thymol is present in an amount of 1% to 10% by weight. In one embodiment, thymol is present in an amount of 1% to 6% by weight. In one embodiment, thymol is present in an amount of 3% to 6% by weight.

[0038] In some embodiments, the compositions of the present invention comprise 0.01% to 35% thymol by weight, in some embodiments, 28% to 33% thymol by weight, and in some embodiments, 0.01% to 1% thymol by weight.

[0039] In the context of the present invention, the compound (c) "5-methyl-2-(propan-2-yl)cyclohexan-1-ol" and "menthol" have the same meaning and are used interchangeably. They refer to the compound having the CAS number 89-78-1, the structure of which is as follows: [ka]

[0040] For the purposes of the present invention, the term "5-methyl-2-(propan-2-yl)cyclohexan-1-ol" is intended to include all possible isomers individually as well as "isomeric mixtures" including them, and racemic mixtures.

[0041] One of the isomers of 5-methyl-2-(propan-2-yl)cyclohexan-1-ol is the compound with CAS number 2216-51-5 and has the following structure: [ka]

[0042] The compositions of the invention comprise 0.1% to 80% menthol by weight. In embodiments, the compositions of the invention comprise 0.5% to 40% menthol by weight. In embodiments, the compositions of the invention comprise 0.5% to 35% menthol by weight. In embodiments, the compositions of the invention comprise 1% to 30% menthol by weight. In embodiments, the compositions of the invention comprise 1.5% to 20% menthol by weight. In embodiments, the compositions of the invention comprise 2% to 15% menthol by weight. In embodiments, the compositions of the invention comprise 2.5% to 12% menthol by weight. In embodiments, the compositions comprise 1% to 10% menthol by weight. In embodiments, the compositions comprise 2% to 5% menthol by weight. In embodiments, the compositions comprise 3% to 4% menthol by weight.

[0043] In an embodiment, the composition of the invention comprises 5% to 35% menthol by weight. In an embodiment, the composition of the invention comprises 8% to 13% menthol by weight. In an embodiment, the composition of the invention comprises 27% to 32% menthol by weight. In an embodiment, the composition of the invention comprises 35% to 80% menthol by weight. In an embodiment, the composition of the invention comprises 60% to 80% menthol by weight. In an embodiment, the composition of the invention comprises 65% to 75% menthol by weight.

[0044] The composition of the invention comprises (a) carvacrol, (b) eucalyptol, and (c) terpinen-4-ol. In some embodiments, the composition consists essentially of (a) carvacrol, (b) eucalyptol, and (c) terpinen-4-ol. In some embodiments, the composition consists essentially of (a) carvacrol, (b) eucalyptol, (c) terpinen-4-ol, and (d) menthol. In some embodiments, the composition consists essentially of (a) carvacrol, (b) eucalyptol, (c) terpinen-4-ol, and (d) menthol. In some embodiments, the composition consists essentially of (a) carvacrol, (b) eucalyptol, (c) terpinen-4-ol, (d) menthol, and (e) thymol. In some embodiments, the composition consists essentially of (a) carvacrol, (b) eucalyptol, (c) terpinen-4-ol, (d) menthol, and (e) thymol. In the context of the present invention, "consisting essentially of" means that certain additional components may be present that do not substantially affect the essential properties of the composition. The present invention also contemplates compositions disclosed in the above or following embodiments, where "consisting essentially of" is replaced with "consisting of."

[0045] The components can be provided from the extract containing them or can be included as pure or nearly pure substances separated from the extract containing them. In all of the above and following embodiments, the active components are preferably included as pure components (rather than as extracts containing them). The advantage of using pure components is that the concentration of the active components in the composition can be tightly controlled, which is important for obtaining the desired combination of active components and for avoiding other substances or contaminants that provide undesirable complexity or toxicity. In this sense, it is noted that extracts are often obtained using solvents that are considered toxic.

[0046] In certain embodiments, the composition consists essentially of: (a) 25% to 43% by weight of carvacrol; (b) 20% to 38% by weight of eucalyptol; and (c) 21% to 38% by weight of terpinen-4-ol; the total of the components adds up to 100% by weight. In certain embodiments, the composition further comprises (d) 0.1% to 9% by weight of thymol. In other specific embodiments, the composition further comprises (d) 1% to 9% by weight of menthol. In some embodiments, the composition further comprises (f) one or more additional active ingredients and / or (g) one or more suitable acceptable excipients or carriers. The total of the components of the compositions of the present invention always adds up to 100% by weight.

[0047] In a more specific embodiment, the composition consists essentially of: (a) 30% to 40% by weight carvacrol; (b) 25% to 36% by weight eucalyptol; (c) 25% to 36% by weight terpinen-4-ol; (d) optionally 1% to 6% by weight thymol; and (e) optionally 2% to 5% by weight menthol.

[0048] In another more specific embodiment, the composition consists of: (a) 30% to 35% by weight carvacrol; (b) 31% to 36% by weight eucalyptol; and (c) 31% to 36% by weight terpinen-4-ol; and does not contain thymol or menthol. In another more specific embodiment, the composition consists of: (a) 35% to 40% by weight carvacrol; (b) 25% to 30% by weight eucalyptol; (c) 25% to 30% by weight terpinen-4-ol; (e) 2% to 5% by weight menthol; and does not contain thymol. In yet another more specific embodiment, the composition consists of: (a) 35% to 40% by weight carvacrol; (b) 25% to 30% by weight eucalyptol; (c) 25% to 30% by weight terpinen-4-ol; (d) 3% to 6% by weight thymol; and (e) 2% to 5% by weight menthol. In some embodiments, the composition further comprises (f) one or more additional active ingredients and / or (g) one or more suitable acceptable excipients or carriers. The total of the components of the compositions of the present invention always adds up to 100% by weight.

[0049] In certain embodiments, the composition consists essentially of: (a) 3% to 25% by weight of carvacrol; (b) 3% to 30% by weight of eucalyptol; and (c) 3% to 55% by weight of terpinen-4-ol; the total of the components totals 100% by weight. In certain embodiments, the composition further comprises (d) 0.1% to 35% by weight of thymol. In other specific embodiments, the composition further comprises (d) 1% to 80% by weight of menthol. In some embodiments, the composition further comprises (f) one or more additional active ingredients and / or (g) one or more suitable acceptable excipients or carriers. The total of the components of the compositions of the present invention always totals 100% by weight.

[0050] In some embodiments, the composition consists essentially of: (a) 5% to 12% by weight carvacrol; (b) 5% to 12% by weight eucalyptol; (c) 5% to 12% by weight terpinen-4-ol; (d) optionally, 0.1% to 6% by weight thymol; and (e) 50% to 80% by weight menthol. In certain embodiments, the composition consists essentially of: (a) 7% to 10% by weight carvacrol; (b) 8% to 11% by weight eucalyptol; (c) 8% to 11% by weight terpinen-4-ol; (d) optionally, 0.1% to 3% by weight thymol; and (e) 65% to 75% by weight menthol.

[0051] In some embodiments, the composition consists of: (a) 2% to 8% by weight carvacrol; (b) 2% to 8% by weight eucalyptol; (c) 40% to 55% by weight terpinen-4-ol; (d) 25% to 35% by weight thymol; and (e) 5% to 15% by weight menthol. In certain embodiments, the composition consists essentially of: (a) 3% to 6% by weight carvacrol; (b) 3% to 6% by weight eucalyptol; (c) 45% to 52% by weight terpinen-4-ol; (d) 27% to 33% by weight thymol; and (e) 7% to 12% by weight menthol. In more specific embodiments, the composition consists essentially of: (a) 15% to 35% by weight carvacrol; (b) 10% to 30% by weight eucalyptol; (c) 10% to 30% by weight terpinen-4-ol; (d) 0.01% to 5% by weight thymol; and (e) 20% to 35% by weight menthol. In even more specific embodiments, the composition consists essentially of: (a) 20% to 25% by weight carvacrol; (b) 21% to 28% by weight eucalyptol; (c) 21% to 28% by weight terpinen-4-ol; (d) 0.01% to 0.1% by weight thymol; and (e) 25% to 35% by weight menthol.

[0052] In some specific embodiments, the compositions disclosed in the above embodiments consist essentially of the disclosed components. In other specific embodiments, the compositions disclosed in the above embodiments consist of the disclosed components.

[0053] In an embodiment, the composition consists essentially of: (a) 5% to 45% by weight carvacrol; (b) 0.5% to 42% by weight eucalyptol; (c) 10% to 57% by weight terpinen-4-ol; (d) 1% to 42% by weight thymol; (e) 0.5% to 40% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight. In an embodiment, the composition consists essentially of: (a) 1% to 43% by weight carvacrol; (b) 1% to 40% by weight eucalyptol; (c) 15% to 55% by weight terpinen-4-ol; (d) 1% to 40% by weight thymol; (e) 0.5% to 35% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight. In an embodiment, the composition consists essentially of: (a) 2% to 43% by weight carvacrol; (b) 2% to 35% by weight eucalyptol; (c) 17% to 54% by weight terpinen-4-ol; (d) 1.5% to 38% by weight thymol; (e) 1% to 30% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight. In an embodiment, the composition consists essentially of: (a) 3% to 43% by weight carvacrol; (b) 3% to 32% by weight eucalyptol; (c) 20% to 53% by weight terpinen-4-ol; (d) 2% to 33% by weight thymol; and (e) 1.5% to 20% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0054] In an embodiment, the composition consists essentially of: (a) 3.5% to 40% by weight carvacrol; (b) 3.5% to 30% by weight eucalyptol; (c) 22% to 52% by weight terpinen-4-ol; (d) 2% to 32.5% by weight thymol; (e) 2% to 15% by weight menthol; and (f) optionally, one or more additional active ingredients; (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0055] In an embodiment, the composition consists essentially of: (a) 4% to 40% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight. In an embodiment, the composition consists essentially of: (a) 15% to 40% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; (e) 2.5% to 12% by weight menthol; and (f) optionally, one or more additional active ingredients; (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0056] In an embodiment, the composition consists essentially of: (a) 25% to 40% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; and (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0057] In an embodiment, the composition consists essentially of: (a) 30% to 40% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; and (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0058] In an embodiment, the composition consists essentially of: (a) 35% to 40% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; and (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0059] In an embodiment, the composition consists essentially of: (a) 4% to 30% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; and (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0060] In an embodiment, the composition consists essentially of: (a) 4.2% to 15% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; and (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0061] In an embodiment, the composition consists essentially of: (a) 4.5% to 10% by weight carvacrol; (b) 4% to 28% by weight eucalyptol; (c) 25% to 50% by weight terpinen-4-ol; (d) 3% to 32% by weight thymol; and (e) 2.5% to 12% by weight menthol; (f) optionally, one or more additional active ingredients; and (g) optionally, one or more suitable acceptable excipients or carriers; the total of the ingredients totaling 100% by weight.

[0062] In certain embodiments, the compositions disclosed in the above embodiments consist essentially of (a)-(c). In other specific embodiments, the compositions disclosed in the above embodiments consist essentially of (a)-(d). In other specific embodiments, the compositions disclosed in the above embodiments consist essentially of (a)-(e). In other specific embodiments, the compositions disclosed in the above embodiments include (a)-(c), and can optionally include (d) and / or (e) as the only active ingredient, preferably as pure ingredients. In other specific embodiments, the compositions disclosed in the above embodiments consist essentially of (a)-(g).

[0063] In embodiments, the compositions are the same as those disclosed below and above, and have a pH of 8 or less. Also, in embodiments, the compositions are the same as those disclosed below and above, and have a pH of 7.5 or less. In embodiments, the compositions are the same as those disclosed below and above, and have a pH of 7 or less. These compositions are particularly advantageous for treating or preventing pathogen infections on biological surfaces, such as the skin, scalp, and soft tissues.

[0064] In embodiments, the compositions are the same as those disclosed below and above, and have a pH greater than 8. Also, in embodiments, the compositions are the same as those disclosed below and above, and have a pH greater than 9. These compositions are particularly advantageous for the treatment or prevention of pathogen infections on inanimate surfaces and for the treatment / prevention of water and air.

[0065] In embodiments, the compositions of the invention further comprise one or more additional active ingredients. In embodiments, the compositions of the invention further comprise one or more additional active ingredients selected from the group consisting of antibiotics, virocides, fungicides, yeasticides, bactericides, skin conditioners, and prebiotics.

[0066] In embodiments, the one or more additional active ingredients are selected from the group consisting of organic acid-containing compounds; quaternary ammonium-containing compounds, such as quaternary ammonium silane salts; methyl n-methylanthranilate; guaiacol; p-cresol, cinnamaldehyde, geraniol, citral, methyl dihydrojasmonate (hedione), 3-(3-propan-2-ylphenyl)butanal (floridral), cis-paramenthanol (cyclohexanemethanol, 4-(1-methylethyl)-, cis-), delta-damascone, eugenol, p-cymene, alpha-pinene, beta-pinene, beta-caryophyllene, caryophyllene oxide, terpinene, and terpinolene. In particular, the one or more additional active ingredients are selected from the group consisting of lactic acid, citric acid, hyaluronic acid, pyruvic acid, ferulic acid, benzalkonium chloride, dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride, methyl n-methylanthranilate; guaiacol; p-cresol, cinnamaldehyde, geraniol, and citral.

[0067] In embodiments, the compositions of the invention further comprise one or more quaternary ammonium-containing compounds; particularly selected from the group consisting of benzalkonium chloride, dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride, and mixtures thereof; particularly from 0.01% to 50% by weight; and more particularly from 5% to 20% by weight. In an embodiment, the composition of the invention further comprises a mixture of methyl n-methylanthranilate; guaiacol; and p-cresol as additional active ingredients; in particular, 0.1% to 25% by weight of methyl n-methylanthranilate; 0.1% to 25% by weight of guaiacol; and 0.1% to 25% by weight of p-cresol. In an embodiment, the composition of the invention further comprises one or more additional active ingredients selected from the group consisting of cinnamaldehyde, geraniol, and citral; particularly from 5% to 20% by weight.

[0068] The compositions of the present invention comprising carvacrol, eucalyptol, terpinen-4-ol, and optionally thymol and / or menthol in the above-described embodiments also apply herein with the addition of one or more of the additional active ingredients described above.

[0069] In an embodiment, one or more active ingredients of the composition are in free form or in particulate form. In an embodiment, one or more active ingredients of the composition are present, individually or in combination, in one or more particulate forms selected from the group consisting of capsules (e.g., microcapsules or nanocapsules), liposomes, and micelles. As described above, the compositions of the present invention can further comprise one or more suitable acceptable excipients or carriers. The appropriate excipients and / or carriers and their amounts can be easily determined by those skilled in the art depending on the type of formulation to be prepared and its intended use. In embodiments, the one or more suitable acceptable excipients or carriers are selected from the group consisting of humectants, surfactants, pH adjusters, gelling agents, solvents, cosolvents, rheological modifiers, preservatives, antioxidants, emulsifiers, stabilizers, chelating agents, flavoring agents, masking agents, opacifying agents, binders, emollients, sweeteners, fragrances, and perfumes. "pH adjuster" refers to an acid or base that can be used to adjust the pH of the finished product to a desired level without affecting the stability of the solution. Examples of suitable pH adjusters include, but are not limited to, acetic acid, lactic acid, citric acid, ethanolamine, formic acid, oxalic acid, potassium hydroxide, sodium hydroxide, triethanolamine, or mixtures thereof.

[0070] "Gelling agent" refers to a compound that forms a gelatinous semi-solid when dissolved, dispersed, or dispersed in a liquid (e.g., an aqueous liquid such as water or a buffer solution). Examples of gelling agents include, but are not limited to, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl guar, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, carbomer, alginic acid, gelatin, gums (e.g., gum arabic, guar gum, gellan gum, xanthan gum), vegetable lecithin, and poloxamer. "Thickener" or "thickening agent" or "viscosity agent" or "rheology modifier" are used interchangeably herein and refer to a material that increases viscosity without substantially altering other properties. Examples of suitable viscosity agents include, but are not limited to, cellulose or its derivatives (e.g., hydroxypropyl methylcellulose), polyethylene glycol, microcrystalline cellulose, cetearyl alcohol, alginates, branched polysaccharides, fused silica, xanthan gum, carbomer, gum, gelatin, and polyacrylates.

[0071] "Solvent" and "co-solvent" refer to substances capable of dissolving or dispersing other substances or ingredients, particularly the active ingredient and / or excipient of the present invention. Examples of solvents include, but are not limited to, water, alcohols such as ethanol, isopropanol, 3-methoxy-3-methyl-1-butanol, glycols such as butylene glycol, dipropylene glycol, dipropylene glycol methyl ether, and tripropylene glycol methyl ether, paraffin and isoparaffin waxes, silicones such as disiloxane and tetrasiloxane, isopropyl myristate, (C12-C15) alkyl benzoates, and mixtures thereof. "Preservative" refers to a material that prevents, reduces, or retards the growth of microorganisms without affecting the stability of the solution. Examples of suitable preservatives include, but are not limited to, benzoic acid, butylparaben, ethylparaben, propylparaben, methylparaben, sorbic acid, potassium sorbate, sodium benzoate, phenoxyethanol, triclosan, or mixtures thereof.

[0072] The terms "filler" and "diluent" have the same meaning and are used interchangeably. They refer to any pharmaceutically acceptable excipient or carrier (material) that complements the size of the composition and makes it practical to manufacture and convenient for the consumer. Materials commonly used as fillers include calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, cellulose, microcrystalline cellulose and its salts, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose, starch or modified starch, magnesium carbonate, magnesium oxide, maltitol, maltidextrin, maltose, mannitol, sorbitol, starch, sucrose, sugar, xylitol, erythritol, and mixtures thereof. In some embodiments, the compositions of the invention comprise one or more pharmaceutically acceptable excipients or carriers containing one or more fillers.

[0073] "Emulsifier" or "emulsifier" are used interchangeably and refer to a material that reduces interfacial tension and promotes the formation of an intimate mixture of incompatible liquids. Emulsifiers stabilize emulsions by increasing their kinetic stability. Examples of suitable emulsifiers include glyceryl trioleate, glyceryl oleate, acetylated sucrose distearate, sorbitan trioleate, polyoxyethylene monostearate, glycerol monooleate, sucrose distearate, polyethylene glycol monostearate, octylphenoxypolyethyleneoxyethanol, diaceryl pentaisostearate, sorbitan sesquioleate, hydroxylated lanolin, lecithin, lanolin, triglyceryl diisostearate, polyoxyethylene oleyl ether, calcium stearoyl-2-lactostearate, and the like. Tolate, sodium lauroyl lactate, sodium stearoyl lactate, cetearyl glucoside, methyl glucoside sesquistearate, sorbitan monopalmitate, methoxypolyethylene glycol-22 / dodecyl glycol copolymer, polyethylene glycol-45 / dodecyl glycol copolymer, polyethylene glycol 400 distearate and glyceryl stearate, candelilla / jojoba / rice bran polyglyceryl-3 esters, cetyl phosphate, potassium cetyl phosphate, or mixtures thereof.

[0074] A "stabilizer" refers to a material that reduces the surface tension of a liquid and the interfacial tension between two liquids, allowing them to spread more easily. Surfactants have hydrophilic heads that are attracted to water molecules and hydrophobic tails that repel water while simultaneously adhering to grease and oil. These opposing forces loosen soils, suspending them in water and allowing them to be removed from human skin, fabrics, and other solid surfaces. Examples of suitable surfactants include, but are not limited to, nonionic, ionic (anionic or cationic), or zwitterionic (or amphoteric, which contains two oppositely charged groups in the surfactant head) surfactants. Examples of anionic surfactants include those based on sulfate, sulfonate, or carboxylate anions (e.g., perfluorooctanoic acid (PFOA or PFO), alkyl benzene sulfonates, soaps, fatty acid salts, or alkyl sulfate salts (e.g., perfluorooctane sulfonate (PFOS), sodium dodecyl sulfate (SDS), ammonium lauryl sulfate, or sodium lauryl ether sulfate (SLES)). Examples of cationic surfactants include those based on quaternary ammonium cations (e.g., cetyltrimethylammonium bromide (CTAB), hexadecyltrimethylammonium bromide, cetylpyridinium chloride (CPC), polyethoxylated tallowamine (POEA), benzalkonium chloride (BA)). C), or benzethonium chloride (BZT). Examples of zwitterionic surfactants include dodecylbetaine, cocamidopropyl betaine, or cocoamphoglycinate. Examples of nonionic surfactants include, but are not limited to, alkyl polyethylene oxide, alkylphenol polyethylene oxide, copolymers of polyoxyethylene and polypropylene oxide (commercially known as poloxamers or poloxamines), alkyl polyglucosides (e.g., octyl glucoside and decyl maltoside), fatty alcohols (e.g., cetyl alcohol and oleyl alcohol), cocamide MEA, cocamide DEA, or polysorbates (e.g., Tween 20, Tween 80, or dodecyldimethylamine oxide).Typically, the amount of surfactant in the composition of the present invention is from 0.01% to 20% by weight.

[0075] The term "humectant" refers to a compound that has hygroscopic properties, attracting or absorbing water molecules from the surrounding environment. Suitable examples include sodium hyaluronate, glycerin, Liponic EG-1, Aqualive, XIVIAC (xylitol), erythritol, hyaluronic acid, sorbitol, collagen, and aloe vera.

[0076] The term "emollient" refers to compounds that soften the skin, reduce dryness and scaling, lubricate the skin surface, promote moisture retention, or modify the texture of the product. Suitable examples include sodium hyaluronate, Saccharin DC, Massocare CO, shea butter oil, dimethicone, lauric acid, and caprylic triglyceride.

[0077] The term "masking agent" refers to a compound that has the ability to reduce or eliminate the sensation of odor and / or bad taste. Suitable examples include trisodium citrate (E331), arginine, sorbitol, triethylene glycol, etc.

[0078] The term "opacifying agent" refers to a substance that has the ability to reduce the transparent or translucent appearance of a cosmetic product and increase its opacity. Suitable examples include Euplan PCO, Lamesoft™, and Tinobis AD.

[0079] The terms "binding agent" and "binder" have the same meaning and are used interchangeably. They refer to a pharmaceutically acceptable excipient or carrier (material) with binding properties. Suitable examples include polyvinylpyrrolidone K30, methylcellulose polymers, hydroxyethyl cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropylmethylcellulose (HPMC), sodium carboxymethylcellulose, carboxymethylene, carboxymethylhydroxyethyl cellulose and other cellulose derivatives, starch or modified starch, and mixtures thereof.

[0080] The term "sweetener" refers to a compound that imparts a sweet flavor and usually provides very low or no energy. Suitable examples include erythritol, sucralose, stevia, fructose, neohesperidin, etc. The term "chelating agent" refers to a compound that binds to soluble (metal) ions by forming a coordination complex at multiple points. Examples of suitable chelating agents include phytic acid, malic acid, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), alpha hydroxy acids, etc. The term "flavoring agent" refers to a compound that complements or enhances the original flavor or taste of a substance. Examples of suitable flavoring agents include sweeteners, mint, strawberry, cherry, lemon, licorice, etc.

[0081] The term "fragrance" refers to a combination of organic compounds that produces a distinctive scent or odor. Examples of suitable fragrances include floral, fruity, woody, musky, etc. The term "perfume" refers to a liquid mixture of compounds used to produce a pleasant scent. Perfumes are composed of fragrant essential oils extracted from plants and spices, and / or synthetic fragrance compounds. Examples of suitable perfumes include floral, fruity, woody, and musky.

[0082] Another aspect of the present invention is a process for preparing the composition of the present invention, as described above.The composition of the present invention can be prepared according to methods known in the art.Appropriate methods and conditions can be easily determined by those skilled in the art based on the type of formulation to be prepared. A second aspect of the present invention relates to a product comprising: (i) an effective amount of the composition defined in the first aspect of the present invention, and (ii) one or more suitable acceptable excipients or carriers. The term "effective amount" refers to the amount of the composition of the present invention that provides the broad-spectrum biocidal activity described above. The effective amount of the composition, which corresponds to an appropriate amount in the product of the present invention, can be determined by one skilled in the art, taking into account the particular pathogen and condition to be treated or prevented in the case, as well as surrounding considerations.

[0083] In one embodiment, the product of the present invention comprises between 0.001% w / w and 50% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.001% w / w and 7% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.001% w / w and 5% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.001% w / w and 4% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.001% w / w and 3% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.01% w / w and 3% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.1% w / w and 3% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 0.2% w / w and 3% w / w of a composition of the present invention. In one embodiment, the product of the present invention comprises between 10% w / w and 50% w / w of a composition of the present invention. In one embodiment, the product of the invention comprises 10% w / w to 25% w / w of a composition of the invention, hi one embodiment, the product of the invention comprises 25% w / w to 50% w / w of a composition of the invention.

[0084] In one embodiment, the product of the present invention comprises 0.1% w / w to 2% w / w of the composition of the present invention. In one embodiment, the product of the present invention comprises 0.1% w / w to 1% w / w of the composition of the present invention. In one embodiment, the product of the present invention comprises 0.1% w / w to 0.5% w / w of the composition of the present invention. For example, the product of the present invention may comprise 0.2%, 0.3%, or 0.4% w / w. The product of the present invention has very high biocidal activity even at very low concentrations. This is due to the synergistic effect of the composition disclosed in the present invention. As demonstrated in the experimental section, the compositions of the present invention are effective against the most common pathogens (including bacteria, fungi, and yeasts) that increase the incidence of disease in humans and animals. This high efficacy and broad spectrum is achieved even when the compositions are used at effective doses as low as 0.01% w / w to 0.3% w / w. In fact, as demonstrated in the experimental section, the compositions of the present invention are effective against pathogens that are resistant to antibiotics (primarily due to their ability to form spores). In such situations, an effective amount of the compositions of the present invention may be 0.1% to 5% w / w of the product. Nevertheless, this amount does not cause undesirable side effects such as resistance or allergies, and also has a very low impact on the environment and ecosystems in which they are obtained or present.

[0085] As noted above, all embodiments relating to the composition of the first aspect of the invention (comprising active ingredients (a)-(e), additional active ingredient (f), and acceptable excipients and carriers) also apply to the product of the second aspect of the invention.

[0086] The appropriate amount of composition (i) and the appropriate amount of excipients and / or carriers can be easily determined by those skilled in the art based on the type of formulation to be prepared and its use. Another aspect of the present invention is a process for preparing the product of the present invention as defined above. The composition of the present invention can be prepared according to methods well known in the art. The appropriate method and conditions can be easily determined by those skilled in the art based on the type of formulation to be prepared.

[0087] Also included as part of the invention are therapeutic uses of the composition of the first aspect or the product of the second aspect, in one embodiment the composition of the first aspect or the product of the second aspect is used as a biocide for use in therapy, or specifically for use in the treatment or prevention of diseases or conditions associated with bacteria, viruses, fungi and yeasts in humans. Examples of diseases or conditions associated with bacteria, viruses, fungi, and yeast include, but are not limited to, human papillomavirus (VPH), hepatitis B virus (HBV), coronaviruses (including SARS-CoV-2), herpes simplex virus (HSV), influenza virus (H7N9), enteric viruses (ECBO), rotavirus (viral colitis), vaccinia virus (smallpox), polyomavirus SV40, bacteriophages of lactobacilli, poliovirus, adenovirus, norovirus (viral colitis), Epstein-Barr virus, poliovirus type 1, LSc-2ab (picornavirus), adenovirus type 5, ATCC VR-5, Maury norovirus (tobamovirus - ToBRFV, strain S99 Berlin), Pseudomonas aeruginosa, Escherichia coli, Coli, Staphylococcus Aureus, Staphylococcus Epidermidis, Staphylococcus Hominis, Enterococcus Hirae, Burkholderia Cepacia, Streptococcus Mutans, Porphyromonas Gingivalis, Fusobacterium Nucleatum, Corynebacterium Xerosis, Micrococcus spp.), Lactobacillus Acidophilus, Gardnerella Vaginalis, Propionibacterium Acnes, Legionella Pneumophila, Proteus Vulgaris, Salmonella Enteritis, Mycobacterium Avium subsp. Paratuberculosis, Listeria Monocytogenes. Fungal spores (Telispore, Zoospore, Ascospore, Zygospore), Bacillus, Clostridium, Xylella fastidiosa, Clostridium difficile, Erwinia amylovora, Xanthomonas arboricola pv. Pruni, Candida albicans, Aspergillus Brasiliensis, Aspergillus niger, Pityrosporum ovale, Campylobacter, Botrytis cinerea, Fusarium, Myristicum, Oidium, Phytophthora, Pythium. Examples of plants include Peronospora tabacina, Phytophthora nicotianae tabaco, Puccinia hordei, Puccinia striiformis, Puccinia recondita, Puccinia graminis, and Puccinia cinnamoni Rands.), Pythium sterilium, Pythiaceae, Botryosphaeria cordite, white rot fungi, Ascomycetes, Xylariales, Biscogniauxia mediterranea, Agrobacterium tumefaciens, Pseudomonas savastanoi, Agrobacterium vitis, etc.

[0088] Thus, the composition of the first aspect of the invention is a pharmaceutical composition, and the suitable acceptable excipient or carrier is a pharmaceutically acceptable excipient or carrier; or, alternatively, the product of the second aspect of the invention is a pharmaceutical product comprising: (i) a therapeutically effective amount of the composition; and one or more pharmaceutically acceptable excipients or carriers. As used herein, a "therapeutically effective amount" refers to an amount of the active ingredient or a composition comprising the same that, when administered, is sufficient to prevent or alleviate to some extent one or more symptoms of a human disease or condition involving bacterial, viral, fungal, or yeast infection. The specific dosage of the active ingredient or composition comprising the same to be administered in accordance with the present invention will, of course, be determined by one skilled in the art, taking into account the particular circumstances surrounding the case, including the particular condition being treated, and similar considerations. And, a "pharmaceutically acceptable excipient or carrier" refers to an excipient or carrier suitable for use in pharmaceutical technology to prepare a composition for medical use.

[0089] In embodiments, the composition according to the first aspect or the product according to the second aspect of the invention is useful for the prevention and / or treatment of skin / scalp / hair diseases or conditions associated with disorders of the sebaceous glands, hi embodiments, the composition according to the first aspect or the product according to the second aspect of the invention is useful for the treatment or prevention of acne, rosacea, eczema.

[0090] In embodiments, the compositions of the first aspect or products of the second aspect of the invention are useful in the prevention and / or treatment of diseases or conditions associated with excessive or abnormal sweating, including hyperhidrosis, chromhidrosis and bromhidrosis.

[0091] Also as part of the present invention, the composition of the first aspect or the product of the second aspect is for use in veterinary medicine. In embodiments, the composition of the first aspect; or alternatively, the product of the second aspect, is for use in veterinary medicine as a biocide, particularly for the treatment or prevention of bacterial, viral, fungal, and yeast diseases or conditions in animals. Examples of bacterial, viral, fungal, and yeast diseases or conditions in animals include, but are not limited to, porcine reproductive and respiratory syndrome (PRRS), influenza A virus subtype H3N8, brucellosis, and the like. Thus, the composition of the first aspect is a veterinary composition, and the suitable acceptable excipient or carrier is a pharmaceutically acceptable excipient or carrier; or, alternatively, the product of the second aspect is a pharmaceutical product comprising: (i) a veterinarily effective amount of the composition; and one or more veterinarily acceptable excipients or carriers. As used herein, a "veterinarily effective amount" refers to the amount of the active ingredient or a composition comprising the same, sufficient, when administered, to prevent or alleviate to some extent one or more symptoms of a disease or condition in an animal associated with bacterial, viral, fungal, or yeast infection. The particular dosage of the active ingredient or composition containing same to be administered in accordance with the present invention will, of course, be determined by one skilled in the art with regard to the particular circumstances surrounding the case, including the particular condition being treated, and similar considerations. And, "veterinary-acceptable excipient or carrier" refers to an excipient or carrier suitable for use in veterinary techniques to prepare compositions for veterinary use. Also as part of the present invention, the composition of the first aspect or the product of the second aspect may be used in cosmetics.

[0092] Thus, the composition of the first aspect of the present invention is a cosmetic composition, and the suitable acceptable excipient or carrier is a cosmetically acceptable excipient or carrier; or, alternatively, the product of the second aspect is a cosmetic product comprising: (i) a cosmetically effective amount of the composition; and one or more cosmetically acceptable excipients or carriers. As used herein, "cosmetically effective amount" refers to an amount sufficient to achieve the cosmetic improvement effect of the skin condition described above. Also, "cosmetically acceptable" refers to an excipient or carrier that is suitable for contact with human skin in non-medical applications without undue toxicity, incompatibility, instability, allergic reaction, etc. The cosmetic compositions of the present invention are designed to be applied to the body to improve its appearance, or to beautify, preserve, condition, cleanse, color, or protect the skin, nails, or hair. Thus, the cosmetic compositions described above are adjectively used for non-medical applications.

[0093] In an embodiment, the cosmetic use of the composition of the first aspect or the product of the second aspect of the invention is as a skin care agent. In an embodiment, the cosmetic use of the composition of the first aspect or the product of the second aspect of the invention is as a skin care agent, including skin care that improves at least one of the following symptoms: roughness, peeling, dehydration, tightness, cracking, lack of elasticity.

[0094] In an embodiment, the cosmetic use of a composition according to the first aspect or a product according to the second aspect of the invention is as a deodorant to reduce, minimize or eliminate odour; in particular body odour or clothing odour.

[0095] In an embodiment, the use in cosmetics of the composition of the first aspect or the product of the second aspect of the invention is as an antioxidant and / or prophylactic agent. The composition of the invention has been shown to retard the degradation / spoilage of ingredients in products containing it, extending the useful life of the final product.

[0096] Also as part of the present invention, the composition of the first aspect or the product of the second aspect is provided for use in agriculture. In an embodiment, the agricultural use of the composition of the first aspect or the product of the second aspect is as a phytosanitary agent; in particular, for the treatment or prevention of bacterial, viral, fungal, and yeast-induced plant diseases or conditions. In an embodiment, the agricultural use of the composition of the first aspect or the product of the second aspect is as a booster agent. The term "booster" refers to a compound that can aid / enhance the effectiveness of other active ingredients, such as other biocides or fertilizers. For purposes of the present invention, the compositions of the present invention can boost the inherent biocidal activity of other biocides, as demonstrated in the experimental section. Thus, they are useful as co-adjuvants for the treatment or prevention of bacterial, viral, fungal, and yeast-induced plant diseases or conditions. Examples of bacterial, viral, fungal, and yeast-induced plant diseases or conditions include, but are not limited to, fire blight, bacterial spot on fruit trees, and bacterial spot on almonds. Thus, the composition of the first aspect is a phytosanitary composition, and the suitable acceptable excipient or carrier is an agriculturally acceptable excipient or carrier; or, alternatively, the product of the second aspect is a phytosanitary product comprising: (i) a phytosanitarily effective amount of the composition; and one or more agriculturally acceptable excipients or carriers. As used herein, a "phytosanitarily effective amount" refers to an amount of an active ingredient, or a composition comprising the same, sufficient, when administered, to prevent or alleviate to some extent the manifestation of one or more symptoms of a plant disease or condition involving bacterial, viral, fungal, and yeast infection of the plant. The specific dosage of an active ingredient, or a composition comprising the same, to be administered in accordance with the present invention will, of course, be determined by one skilled in the art with respect to the particular circumstances surrounding the case, including the particular condition being treated, and similar considerations. And, an "agriculturally acceptable excipient or carrier" refers to an excipient or carrier suitable for use in agriculture to prepare a composition for phytosanitary use.Examples of agriculturally acceptable excipients or carriers include, but are not limited to, plant strengtheners, nutrients, humectants, compounds that improve adhesion, buffering compounds, stabilizers, antioxidants, osmoprotectants, sunscreens, and the like.

[0097] One embodiment of the present invention contemplates that the composition of the first aspect is a dietary supplement and the suitable and acceptable excipient or carrier is an edible excipient or carrier, or alternatively, that the product of the second aspect is a dietary supplement comprising: (i) an effective amount of the composition and one or more edible excipients or carriers. For purposes of this invention, the terms "dietary supplement," "food / feed supplement," or "nutraceutical" refer to compositions or products intended to supplement the diet and provide nutrients, such as vitamins, minerals, fiber, fatty acids, or amino acids, that may be deficient or not consumed in sufficient amounts in the normal diet, and are used interchangeably. The term "edible" refers to compounds, compositions, complexes, salts, esters, excipients, and carriers that can be consumed by humans or animals without significant adverse health effects, meaning that they are suitable for consumption. For purposes of this invention, "food / feed grade" and "edible" are equivalent and refer to both for human and animal consumption. The specific dose of active ingredient to be administered in accordance with this invention will be determined by a skilled artisan, taking into account the specific circumstances surrounding the case.

[0098] The term "edible excipient or carrier" refers to an excipient or carrier that is suitable for use in preparing compositions or products that can be consumed by humans or animals without significant adverse health effects.

[0099] Also included as part of the present invention are uses of the composition of the first aspect or the product of the second aspect in the hygiene / disinfection / cleaning field.

[0100] In one embodiment of the present invention, the composition of the first aspect, or alternatively, the product of the second aspect, is useful as a disinfectant. Thus, the composition of the first aspect is a disinfectant composition and includes a suitable and acceptable excipient or carrier. Alternatively, the product of the second aspect is a disinfectant product comprising: (i) a disinfectant-effective amount of the composition and one or more acceptable excipients or carriers. The term "disinfectant" refers to a product that kills microorganisms on inanimate objects or spaces. Examples include hard surfaces, medical instruments, surgical instruments, and air. As used herein, the phrase "disinfectant-effective amount" refers to an amount of an active ingredient or a composition containing the same sufficient to kill bacteria, viruses, fungi, and yeasts from an inanimate surface or space. The specific dosage of the active ingredient or composition containing the same to be administered in accordance with the present invention can be determined by a skilled artisan, taking into account the specific circumstances surrounding the case. Suitable excipients or carriers for disinfectant applications can be any of those commonly used in disinfectant or antiseptic compositions disclosed in the prior art. For example, the excipient or carrier may be selected from the following group: colorants, flavors, solvents such as glycols, diluents such as water, surfactants such as anionic surfactants, stabilizers, and rheology modifiers. Disinfecting applications of the compositions of the present invention and products containing them include, but are not limited to, disinfecting instruments, equipment, facilities, air (environmental hygiene), surfaces, and clothing in both domestic and professional care services. Specific examples include disinfecting baby bottles and nipples, facilities (toilets, kitchens, hotels, sanitary facilities—hospitals, adult and youth housing, sports centers, commercial facilities, conference rooms), vehicles (airplanes, buses, cars, motorcycles), and water treatment (wastewater treatment and drinking water treatment). As noted above, the effectiveness of the compositions of the present invention has been confirmed to be higher and longer-lasting than that exhibited by bleach.

[0101] Also included as part of the present invention is the use of the composition of the first aspect or the product of the second aspect in the food / feed industry. In one embodiment, the composition of the first aspect of the present invention is a food / feed additive, and the suitable acceptable excipient or carrier is an edible acceptable excipient or carrier. Alternatively, the product of the second aspect of the present invention is a food / feed additive comprising: (i) an effective amount of the composition and one or more edible acceptable excipients or carriers. The term "food / feed additive" as used herein refers to a composition or product added to food / feed to maintain or improve its safety, freshness, taste, texture, or appearance. The specific dosage of the active ingredient to be administered in accordance with the present invention will be determined by a skilled artisan, taking into account the particular circumstances surrounding the case.

[0102] In an embodiment, the use of the composition of the first aspect of the invention, or the use of the product of the second aspect, is in the food / feed industry selected from the group consisting of: food / feed preservatives, food / feed antioxidants, food / feed antiseptics, food / feed biocides, and technical aids. The present invention also includes the use of the composition of the first aspect or the product of the second aspect in the fragrance / perfume sector. In one embodiment, the composition of the first aspect of the invention is a fragrance composition and includes a suitable and acceptable excipient or carrier. Alternatively, the product of the second aspect of the invention is a fragrance product comprising: (i) an effective amount of the composition and one or more acceptable excipients or carriers. "Suitable and acceptable" in the context of the fragrance compositions and products of the invention refers to an excipient or carrier suitable for the preparation of a fragrance article having fragrance applications, particularly in the cosmetics and fragrance fields. "Fragrance" refers to any article intended for consumers that includes a composition or product of the invention. In one embodiment, the fragrance article of the invention takes the form of a fragrance. Examples of fragrance products of the invention include fragrances. "Fragrance" refers to a fragrance article that includes the composition of the invention and contains an aroma / fragrance / perfume. The fragrance article is intended to be in contact with the air of a space, either a closed interior space such as a room or closet, or an open space.

[0103] Part of the present invention includes the use of the composition of the first aspect or the product of the second aspect in the field of beekeeping. Bees are important insects for the Earth. However, they are highly sensitive and are greatly affected by many environmental threats resulting from pesticides, air and water pollution, deforestation, and other human activities. As a result, bee populations have declined dramatically over the past few decades, threatening life on Earth itself. The inventors have discovered that the composition of the present invention can be effectively used in beekeeping. A product containing 0.2% of a composition according to the present invention (composed, by weight, of 35-40% carvacrol, 25-30% eucalyptol, 25-30% terpinen-4-ol, 3-6% thymol, and 2-5% menthol) was applied by nebulization to varroa-infested hives. This treatment successfully eliminated the parasites without adversely affecting the bees. This is extremely surprising, especially considering that Varroa mites are resistant to common biocides and, more importantly, that honeybees are highly sensitive to biocides. Furthermore, the bees were not repelled by the treatment, and life and activity in the hive continued as normal after treatment. Due to its surprising effectiveness and low toxicity, the composition of the present invention has achieved something that few other disinfectants have achieved in beekeeping.

[0104] As part of the present invention, the use of the composition of the first aspect or the product of the second aspect is included in the following applications:

[0105] Used as a preservative in wood treatment, a domestic and commercial air disinfectant (for use with electrically powered devices or rechargeable or disposable batteries, single charge or with pre-charge), a beehive disinfectant, a bee feed supplement for the removal of pathogens (including, by way of example and not limitation, varroa), a fuel preservative and antioxidant, a preservative in detergents and fabric softeners, an antiseptic and taxidermy liquid, a film preservative (intended to preserve paints and coatings and to control microbial deterioration and algal growth to protect the original surface properties of paints, plastics, sealants, wall adhesives, binders, paper or artwork), a protectant for textiles, leather, rubber and polymeric materials, a preservative for building materials, a mildew inhibitor, a protectant in liquids used in machining or cutting materials, or in products to control microbial spoilage in liquids used in machining or cutting metal, glass and other materials.

[0106] The compositions and products of the present invention can be formulated in a variety of forms depending on the route of administration / application, the type of galenic preparation, and the intended field.

[0107] In one embodiment, the composition or product is comprised in a galenic form selected from the group consisting of solutions, aerosols, non-aerosol sprays, sprays, shaving creams, powders, mousses, lotions, emulsions, gels, sticks, oils, ointments, pastes, creams, shampoos, shower gels, body washes, face washes, bar soaps, capsules, microcapsules, suspensions, liposomes, pellets, patches, and shower salts.

[0108] In one embodiment, the composition or product is useful in the pharmaceutical, veterinary, cosmetic or food / feed fields and the route of administration is selected from the group consisting of oral, buccal and topical.

[0109] In the description and claims, the word "comprises" and variations thereof are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprises" also encompasses the case of "consisting of." Additional objects, advantages, and features of the present invention may become apparent to those skilled in the art upon examination of the description or may be learned by practicing the invention. The following examples and drawings are provided as illustrative examples and are not intended to limit the present invention. Where reference signs relating to the drawings are placed in parentheses in the claims, this is an attempt to facilitate understanding of the claims and should not be construed as limiting the scope of the claims. Furthermore, the present invention encompasses all possible combinations of the specific and preferred embodiments described herein.

[0110] Example A. General Considerations Carvacrol, eucalyptol, terpinen-4-ol, thymol, menthol, methyl N-methylanthranilate, guaiacol, p-cresol, dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride, benzalkonium chloride, and the surfactant polysorbate 20 are commercially available in food / feed grade from GUINAMA.

[0111] All bacterial, fungal, and yeast strains are available from ATCC (https: / / www.lgcstandards-atcc.org / en / About / About_ATCC / Who_We_Are.aspx). All of these strains were used as example bacterial, fungal, and yeast strains to perform biocidal testing of the compositions claimed in this application. Other strains may be used as well to demonstrate the claimed biocidal efficacy. Therefore, these strains are not directly related to the purpose or focus of the invention.

[0112] B. Minimal Composition of the Present Invention Minimum inhibitory concentration (MIC) test The purpose of the tests described in the following sections was to determine the minimum inhibitory concentrations (MICs) of the minimal composition of the present invention (Composition 1) and other compositions (Compositions 2-3) and compare them to the MICs of each component alone (carvacrol, eucalyptol, terpinen-4-ol, thymol, and menthol). The compositions shown in Table A were tested against the microorganism Pseudomonas aeruginosa and bacterial biofilms. The compositions are shown in Table A.

[0113] [Table 1]

[0114] Preparation procedure for compositions 1-3: Step 1: Each ingredient was weighed out separately. Step 2: Carvacrol, terpinen-4-ol, and eucalyptol were mixed together under slow stirring. Step 3: The resulting mixture was heated at a temperature range of 40-50°C. Step 4 (for compositions 2 and 3): Menthol was added and stirring was continued until it was completely dissolved in the temperature range of 60-80°C. Step 5 (for composition 3): Solid thymol was added to the resulting mixture and heated at a temperature range of 60-80°C until the thymol was dissolved. Step 6: Once dissolution was confirmed, the temperature was reduced.

[0115] Test description: An initial inoculation of the microorganism of interest was performed on the surface. After inoculation, an initial sampling was performed before starting the process of applying the product to different surfaces. For this, a sterile cotton swab was used to take the surface sample. To take the surface sample, a moistened cotton swab was used. The swab was removed from its sterile packaging and dipped into a tube containing diluent / neutralizer to moisten the tip. The tip of the swab was pressed against the side of the tube to remove excess diluent / neutralizer. The tip of the swab was placed on the surface to be investigated and held approximately 100 cm 2The area of each sample was estimated and rubbed on each area while simultaneously rotating the handle of the swab between the thumb and index finger. Sampling was performed 10 times in both the vertical and horizontal directions. The collected swabs were placed back into their respective tubes, which were then sealed to keep them moist until analysis. After the initial sampling, the process of applying the product to different surfaces at different concentrations began. No water rinse was required after the product was applied. Samples were taken from the different surfaces 1 minute after product application. Sampling was performed according to the method described for the initial sampling (T=0). All samples taken after the sampling process was completed were refrigerated for storage until analysis.

[0116] After the sampling process was completed, testing for microorganisms of interest was performed in the laboratory by culture plating on selective media, always following the following procedure:

[0117] Starting with the initial solution, a dilution series was prepared in TSB medium to obtain samples at different concentrations for each microorganism to be inoculated. This method allows for initial screening to determine at what concentration the minimum inhibitory concentration (CIM) fluctuates through turbidity. In this test, initial dilutions were prepared for each strain at the following concentrations: 1% (0.01 g / mL), 0.1% (1 mg / mL), 0.01% (0.1 mg / mL), 0.001% (0.01 mg / mL), and 0.0001% (0.001 mg / mL). All tubes with different concentrations were inoculated with each strain and incubated for 48 hours at 37°C. To ensure the correct functioning of the technique used and to obtain reliable results, the following was also set: Negative control sample: Sample + TSB Process negative control (C-): TSB medium Positive control (C+): TSB medium + inoculum

[0118] Using the results from the initial screening, a new dilution bank was created in TSB medium to identify the concentration between no growth and the concentration at which bacterial growth was observed. In this way, the target minimum inhibitory concentration (MIC) could be adjusted. Each tube was inoculated with a different bacterial strain. At this stage, each tube was plated and counted, and the MIC on the plate was also observed. The tubes were then incubated at 37°C for 48 hours. After the incubation time, the tubes and plates were read and the lowest concentration at which no growth was observed was observed. This was the minimum inhibitory concentration (MIC). The test results for Pseudomonas aeruginosa (ATCC 15442) are shown in Table B.

[0119] [Table 2] Table C shows the results of bacterial biofilms (Listeria monocytogenes ATCC 35152, Aerobio 30 0 ATCC 25922, Clostridium sporogenes ATCC 19404, Candida albicans ATCC 26555, Escherichia coli ATCC 10536).

[0120] [Table 3]

[0121] The results shown in Tables B and C reveal that the combination of carvacrol, terpinen-4-ol, and eucalyptol exhibits a surprisingly low MIC (minimum inhibitory concentration) compared to the MICs of each individual component. This proves that the minimum composition of the present invention has an unexpected synergistic effect between the three components. The addition of thymol and menthol further improved the effectiveness of the minimum composition.

[0122] Biocidal effect The purpose of this test is to evaluate the biocidal activity of compositions 1 and 2 defined in the previous examples (both used at 0.2% in water) against the microorganisms Pseudomonas aeruginosa (ATCC 15442) and coronavirus (ATCC CCL-171).

[0123] Test Description: An initial inoculation of the microorganism of interest was performed on the surface as described in Section 1.1. After application of the product, samples were taken from different surfaces at 1, 3, and 7 minutes. Sample collection was performed according to the sampling method described for initial sampling (T=0). After the sampling process was completed, all samples were refrigerated for storage. After the sampling process was completed, testing for target microorganisms was performed in the laboratory. Testing was performed by culture on selective media according to the UNE-EN 13697:2015 standard. [Table 4]

[0124] Considering the results obtained, it can be concluded that under the conditions described, these two compositions have a biocidal effect against Pseudomonas aeruginosa and coronaviruses 1 minute after application.

[0125] C. Other compounding examples (Examples 1-22) Examples 1-22 illustrate additional compositions of the present invention, which include a combination of the active ingredients carvacrol, eucalyptol, terpinen-4-ol, thymol, and menthol.

[0126] Tables 1-4 disclose the quantitative formulations of the compositions of Examples 1-22, with the amounts of food / feed grade ingredients or essential oils containing them shown as the weight % of the ingredient relative to the total weight of the composition. [Table 5] [Table 6] [Table 7]

[0127] The process for preparing the compositions of Examples 1-22 involves mixing the ingredients of each example listed in the table above in the specified order at different temperatures until completely dissolved, then cooling to room temperature before packaging and preparation.

[0128] General Preparation Process for Examples 1-5 and 18-22 Step 1: Weigh out each ingredient separately. Step 2: Mix carvacrol, terpinen-4-ol, and eucalyptol at low speed. Add solid thymol to the resulting mixture. Step 3: The mixture is then heated to a temperature of 60-80°C until the thymol is completely dissolved. Step 4: Next, add the menthol and continue stirring until it is completely dissolved while maintaining the temperature in the closed reactor. Step 5: After dissolution is achieved, the temperature is reduced to room temperature.

[0129] General Preparation Process for Examples 6-9 This process includes: Follow steps 1 and 2 above. The resulting mixture is heated to 50 to 60°C, and guaiacol and N-methylanthranilate are added in that order and completely dissolved. Then, follow steps 3 and 4 above. To the resulting mixture, p-cresol is added and completely dissolved. Finally, perform step 5.

[0130] General Preparation Process for Examples 10-13 This process includes: Follow steps 1 to 5 above. To the resulting mixture, polysorbate 20 is added with stirring at 50-60°C. Then benzalkonium chloride and then dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride are slowly added. Finally, perform step 5.

[0131] General Preparation Process for Examples 14-16 This process includes: Follow steps 1 and 2 above. To the resulting mixture, cinnamaldehyde, geraniol, and citral are added sequentially and individually at a temperature of 60-80°C. Finally, perform steps 3 to 5.

[0132] Products of the Invention The products of the present invention are comprised in concentrations ranging from 0.05% w / w to 5% w / w. For example, to obtain a product with a 1% w / w concentration of the composition of the present invention, 0.01 g of the composition is required for every 100 g of total product weight.

[0133] The process for preparing products for the antibacterial testing of the present invention involves diluting the compositions of Examples 1-23 with deionized water, optionally with one or more suitable excipients or carriers, and one or more additional active ingredients, until the appropriate concentration, expressed weight / weight, is reached.

[0134] Comparative Examples Outside the Scope of the Invention (Comparative Examples 1 to 4) Comparative Examples 1 to 4 show compositions that do not contain the combination of 5-isopropyl-2-methylphenol (carvacrol), 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol), 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol), 5-methyl-2-(propan-2-yl)phenol (thymol), and 5-methyl-2-(propan-2-yl)cyclohexan-1-ol (menthol), which are the active ingredients of the present invention. In particular, comparative compositions may include none of one or more ingredients, or may include all ingredients, but at least one ingredient may be present in an amount outside the claimed range.

[0135] Table 5 lists the quantitative compositions of Comparative Examples 1-4, with the amounts of food / feed grade ingredients shown as the weight percentage of the ingredient relative to the total weight of the composition. [Table 8]

[0136] Corresponds to Example 4 of European Patent Application EP 0244363 (without chlorhexidine)

[0137] The preparation process for the compositions of Comparative Examples 1 and 4 is carried out using the general process for preparing the composition of Inventive Example 1, using the amounts of each component shown in Table 5 above. The preparation process for the compositions of Comparative Examples 2 and 3 uses the general process for preparing the composition of Inventive Example 1, but using only the components included.

[0138] Biocide Analytical Testing 4.1. Antibacterial analytical testing The purpose of the antimicrobial assay test is to determine the lowest concentration of the composition of the present invention that can inhibit the growth of a particular bacterial strain.

[0139] The procedures adopted to demonstrate antibacterial activity follow the European standard protocol UNE-EN 1276:2010 for bactericidal testing in the medical field and surface disinfection conditions. Suitable concentrations of the compositions included in the products of the present invention are disclosed below.

[0140] The results for the compositions of Examples 1, 3, 4, 5, 11, 12, 13 and 14 are as follows according to the standard: [Table 9]

[0141] Examples 15 and 16 The results of the composition are as follows according to the standard: [Table 10]

[0142] The results for the composition of Example 17 are as follows, based on the standard: [Table 11]

[0143] These results demonstrate that the compositions of the present invention are suitable for inhibiting the growth of the most common bacterial pathogens even at very low concentrations (0.005-0.1% (w / w)).

[0144] Other studies have been performed on Legionella pneumophila ATCC 33152, Listeria monocytogenes ATCC 35152, and spores of Bacillus, Clostridium, and fungi (theriospores, basidiospores, and ascospores). Under soiled conditions, concentrations of 0.1%, 0.2%, and 0.3% of the first example composition (in accordance with UNE-EN-13697 guidelines) were able to reduce the concentration of Legionella pneumophila ATCC 33152 to less than 10^-3 after 5 minutes. On the other hand, several stainless steel surfaces were inoculated with spores (fungi, bacillus, clostridium) and Listeria monocytogenes ATCC 35152. After 5 minutes, the composition of Example 1 (in accordance with UNE-EN-13697:2015 guidelines) using the above-mentioned dilutions of 0.1%, 0.2%, and 0.3% (w / w) was found to inhibit the growth of all pathogens. Therefore, the presence of microorganisms was not detected.

[0145] 4.2. Antiviral analytical tests The antiviral activity of the compositions of the present invention was tested. method: The method is based on UNE-EN 14476:2014 + A1. Compositions tested: Compositions of Examples 1, 3, 4, 5, 11, 12, 13, 14. result The concentrations of the compositions tested and the time required to inhibit the growth of the most important viral pathogens under clean and dirty conditions are shown. The results for clean conditions and in accordance with the method are as follows: [Table 12]

[0146] The results according to the standard method under dirty conditions are as follows: [Table 13]

[0147] These results show that the compositions of the present invention are suitable for eliminating the most important viral pathogens, even at low concentrations of 0.1-0.2% (w / w).

[0148] 4.3. Antifungal and antiyeast analytical tests The activity of the compositions of the present invention was tested. Test 1 method: The method is based on the UNE-EN 1276: 2010 standard for Aspergillus brasiliensis and the UNE-EN 1650: 2008 + A1 standard for other fungi and yeasts. Compositions tested: Compositions of Examples 1, 3, 4, 5, 11, 12, 13, 14.

[0149] result The concentrations of the compositions tested and the time required to inhibit the growth of fungi and / or yeasts in compliance with the corresponding standard methods mentioned above are given: [Table 14]

[0150] Test 2 method: The method is based on UNE-EN-13697:2015. Compositions tested: Compositions of Examples 1, 3, 4, 5, 11, 12, 13, 14.

[0151] result The concentrations of the compositions tested and the time required to inhibit the growth of fungi and / or yeasts in compliance with the corresponding standard methods mentioned above are given: [Table 15]

[0152] These results demonstrate that the compositions of the present invention are effective against fungi and yeasts even at concentrations as low as 0.007 to 0.1% (w / w).

[0153] Comparative antibacterial test An antibiotic test was conducted comparing composition example 1 of the present invention with comparative examples 1-3.

[0154] method: The differences in antibacterial activity of different test compositions against Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538, and Enterococcus hirae ATCC 10541 were measured according to the UNE-EN 1276:2010 standard.

[0155] result: The minimum inhibitory concentrations (MICs) of the individual active ingredients are shown in Table B. Also, the concentrations of Inventive Composition Example 1 and Comparative Examples 1-3 capable of inhibiting microbial growth were determined, and the results are shown for the microorganisms tested: [Table 16]

[0156] These results clearly demonstrate that only the compositions of the present invention containing specific combinations of active ingredients, as shown in the table above, exhibit effective antibacterial activity against the most important bacterial pathogens. On the other hand, Comparative Composition Example 1 (containing carvacrol and eucalyptol in amounts outside the scope of the present invention) required much higher concentrations to combat all tested pathogens. Furthermore, it was revealed that combinations that did not contain the main ingredients (carvacrol, terpinen-4-ol, and eucalyptol) (Comparative Example 3: containing eucalyptol, thymol, and menthol; or Comparative Example 2: containing terpinen-4-ol and carvacrol) failed to achieve the surprising antibacterial effect. These results demonstrate that the compositions of the present invention exhibit synergistic effects by combining the five ingredients at specific concentrations.

[0157] 4.5. Conclusion Therefore, the compositions of the present invention are effective as broad-spectrum biocides by eliminating pathogens such as bacteria, viruses, fungi, yeasts, etc. The compositions of the present invention are particularly advantageous in that they maintain their biological activity even at low concentrations (0.005% to 2% w / w).

[0158] In vivo biocidal analytical testing 5.1. Antibacterial activity test in wastewater The antibacterial capacity of the composition of the present invention is 10 per ml 6 coliform bacteria and 10 per ml 4The evaluation was carried out using municipal wastewater containing enterococci, collected from EDAR Emasesa and EDAR Aljarafesa.

[0159] Tested Compositions The following compositions were tested: The products of Examples 1, 3, 4, 5, 6, 7, 8, 9, and 10 of the present invention were diluted 20 times, 40 times, 50 times, 75 times, and 100 times, respectively, i.e., Products 1.20 to 1.100, Products 2.20 to 2.100, Products 3.20 to 3.100, Products 4.20 to 4.100, Products 5.20 to 5.100, Products 6.20 to 6.100, Products 7.20 to 7.100, Products 8.20 to 8.100, Products 9.20 to 9.100, and Products 10.20 to 10.100.

[0160] method In this method, 100 ml of filtered wastewater was diluted with the product of the present invention at concentrations ranging from 0.098% to 25% and the antibacterial activity against aerobic bacteria (e.g., Pseudomonas aeruginosa) was evaluated. The mixture was stirred for 1 minute at 22°C and then incubated for 2 days.

[0161] result All tested compositions exhibited effective biocidal activity against the tested bacteria at all tested concentrations, even the lowest concentration.

[0162] 5.2. Antibacterial activity testing in the environment Air is a carrier medium for aerobic mesophilic bacteria and their spores, which can cause contamination of food / feed and surfaces, as well as infectious diseases (skin and respiratory diseases) in humans and animals. Mesophilic bacteria include all bacteria, molds, and yeasts capable of growth at 22°C. Measuring the number of these microorganisms reflects the hygienic quality of the air and handling conditions and is an indicator of contamination. Furthermore, certain microorganisms that are not normally pathogenic can cause disease if present in large quantities, so their detection provides important information for assessing the effectiveness of treatment.

[0163] Tested Compositions The composition tested was that of Example 1 (concentration 0.2% w / w).

[0164] method To evaluate the antimicrobial potential of the compositions of the present invention, the tested compositions were used in a 65 ml 2 The spray test was carried out in a room. After spraying, air samples (0.001 m 3 ) was collected from 0.01 m of air. 3 The samples were collected by filtration and then bombarded onto agar plates using a VWR DUO SAS Super 360 sampler. The number of bacteria grown on the agar plates was then counted and the number of bacteria in the air was determined using the plate colony count method (UNE EN 1276 and UNE EN 1500 standards).

[0165] result In the analysis of the agar medium, no bacteria (aerobic), mold, or yeast was detected after 15 minutes of exposure after spraying the composition of the present invention (0 cfu / m 3 ). Thus, these analytical results demonstrate that the compositions of the present invention are highly effective in eliminating pathogenic elements present in the environment. 5.3. Antibacterial Activity Test on Hands (as an Antiseptic) The antimicrobial activity of the compositions of the present invention was also evaluated in a hand friction test.

[0166] Tested Compositions :Compositions of Examples 1, 3, 4, 5, 11, 12, 13, and 14.

[0167] method :In accordance with UNE-EN 1500:2013 standard.

[0168] result The concentrations of the compositions tested and the contact time (45 seconds + 5 seconds) required to inhibit bacterial growth on hands were as follows: E. coli ATCC 10536: 0.1% (w / w)

[0169] 5.4. Antimicrobial activity on inanimate surfaces (disinfectants) The attachment and subsequent proliferation of microorganisms on material surfaces is a major concern in many biomedical applications, as well as in the agricultural food / feed industry and household hygiene. Short-term evaluation

[0170] Compositions tested: The compositions of Examples 1, 3, 4, 5, 11, 12, 13, and 14 were prepared in dilutions ranging from 0.0001% to 2% (w / w).

[0171] method To evaluate the ability of the compositions of the present invention to prevent microbial growth on inanimate surfaces, stainless steel, polyvinyl chloride (PVC), and polyurethane (PU) disks were used, which had been previously disinfected and washed with distilled water. The tested compositions were used to impregnate different disks. After drying for 1 hour, bacterial suspensions of Pseudomonas aeruginosa (ATCC 15442), Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 10536), Candida albicans (ATCC 10231), and Aspergillus brasiliensis (ATCC 16404) were added individually. After 30 minutes of contact, the mixtures were applied to Petri dishes and incubated for 24–48 hours.

[0172] result At appropriate concentrations of the composition of the present invention, a complete absence of colonies was observed on the medium on all tested surfaces (stainless steel and plastic surfaces).

[0173] Results for compositions of Examples 11, 12, 13, 14: [Table 17]

[0174] Results for compositions of Examples 11, 12, 13, 14: [Table 18]

[0175] Long-term evaluation details Compositions tested: The compositions of Examples 11, 12, 13 and 14 were prepared in dilutions ranging from 0.0001% to 2% (w / w).

[0176] method The same method as above was used, except that the soaked discs were allowed to dry for 15 days before being inoculated with the bacterial suspension.

[0177] result It was confirmed that the bactericidal effect of the tested compositions remained unchanged after 15 days.

[0178] This study demonstrated that the compositions of the present invention retain their effectiveness when combined with polymeric and non-polymeric cationic compounds such as benzalkonium chloride and dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride.

[0179] 5.5. Antibacterial Testing of the Compositions of the Present Invention in Combination with Other Antibiotics (Booster Antibiotic Function) The use of disinfectants with bactericidal and antiviral properties is very common in the treatment of surfaces and other objects in daily use. Their presence on the market has been very common for the last few decades. This has led to the emergence of a wide range of substances and combinations that are more or less effective against certain microorganisms. However, some of these disinfectants lose their effectiveness after a few days, allowing the growth of microorganisms again.

[0180] The purpose of this study is to evaluate well-known, approved disinfectants in the treatment of sterilized containers, with and without the complementary action of the composition of the present invention.

[0181] Compositions tested: Treatment A: Known disinfectant (lactic acid) Treatment B: Composition of Example 1 of the present invention Treatment C: Known disinfectant (lactic acid) + composition of Example 1 of the present invention

[0182] Bacteria tested (1) Pseudomonas aeruginosa ATCC 15 442, Escherichia coli K12 CECT 433, Staphylococcus aureus ATCC 6 538, Enterococcus ATCC 10 541

[0183] Viruses tested (2) Poliovirus ATCC VR-166, Adenovirus ATCC VR-1516 Norovirus ATCC TIB-71

[0184] method Treatments A, B, and C were applied according to standardized operating procedure PNT.08.93 and differences were investigated 10 days after treatment on sterile plastic containers. Results Tests were conducted on various surfaces exposed to the aforementioned bacteria and viruses. The bactericidal and antiviral activities of treatments A, B, and C were then measured. Additionally, the percentage effectiveness of the tested compositions against these microorganisms was calculated. The percentage effectiveness was calculated based on the total of all tested microorganisms. The percentage effectiveness obtained for each treatment is shown in the table below. [Table 19]

[0185] As shown in the table above, combining a disinfectant treatment with a composition of the present invention significantly increased both disinfectant and antiviral activity, in fact more than doubling the effectiveness of the disinfectant alone and approaching 100% of the effectiveness of the composition of the present invention alone. It can therefore be concluded that the compositions of the present invention can be combined with known fungicides to exert a synergistic effect, not only improving their biocidal efficacy but also prolonging their efficacy over time.

[0186] 6. Pharmaceuticals containing the compositions of the present invention product The following products were prepared using the compositions of the present invention: Product 1 Hand sanitizing gel containing 1% (w / w) of the composition of Example 3: [Table 20]

[0187] Preparation process: Step 1: Disperse the ingredients in the order listed in the table and stir at room temperature. Step 2: Add the mixture from Phase A to Phase B, water. Step 3: Add the Polyquaternium-10 from Phase C to the mixture obtained in the previous step with gentle stirring and continue stirring until completely dispersed.

[0188] Product 2 Intimate soap containing 0.3% (w / w) of the composition of Example 1: [Table 21]

[0189] Preparation process: Step 1: Dissolve Phase A ingredients. Step 2: Dissolve the ingredients of Phase B in water and add to Phase A with stirring. Step 3: Disperse the ingredients of Phase C and add to the AB mixture with stirring. Step 4: Add the ingredients of Phase D to the AB mixture one by one and mix until a smooth paste is formed. Step 5: Add the ingredients of Phase E to the ABCD mixture with gentle stirring.

[0190] Product 3 A moisturizing gel containing 0.1%, 0.2%, or 0.3% (w / w) of the composition of Example 1: [Table 22]

[0191] Preparation process: Step 1: Dissolve Phase A ingredients. Step 2: Dissolve the ingredients of Phase B in water and add to Phase A with stirring.

[0192] Product 4 A hand cream containing 0.2% (w / w) of the composition of Example 10: [Table 23]

[0193] Preparation process: Step 1: Dissolve Phase A ingredients. Step 2: Dissolve the ingredients of Phase B in water and add to Phase A with stirring. Step 3: Dissolve the ingredients of Phase C and add to the AB mixture while stirring. Step 4: Dissolve the ingredients of Phases D and E in water and add to the AB mixture with very light stirring.

[0194] Product 5 Hand sanitizing cream containing 0.2% (w / w) of the composition of Example 1: [Table 24]

[0195] Preparation process: Step 1: Dissolve glycerin in water. Step 2: Dissolve the ingredients of Phase B in Phase A with stirring. Step 3: Dissolve the ingredients of Phase C and add to the AB mixture with stirring. Step 4: Add the ingredients of Phase D to the AB mixture in order and mix until a smooth paste is formed. Step 5: Add the ingredients of Phase E to the ABCD mixture with very light stirring.

[0196] Product 6 Vaginal gel containing 0.3% (w / w) of the composition of Example 5: [Table 25]

[0197] Preparation process: Step 1: Dissolve all ingredients of Phase A in water. Step 2: Dissolve the ingredients of Phase B in water and stir while heating at 50°C. Step 3: Add Phase B to Phase A.

[0198] Product 7 Toothpaste containing 0.2% (w / w) of the composition of Example 13: [Table 26]

[0199] Preparation process: Step 1: Disperse Cosfaderm X34 in glycerin and sorbitol, then add water and stir gently to form a gel. Step 2: Dissolve the ingredients of Phase B in water and add to Phase A with stirring. Step 3: Disperse the ingredients of Phase C and add to the AB mixture with stirring. Step 4: Add the ingredients of Phase D to the ABC mixture one by one and mix until a smooth paste is formed. Step 5.: Add the ingredients of Phase E to the ABCD mixture with very light stirring.

[0200] Product 8 Mouthwash containing 0.2% (w / w) of the composition of Example 14: [Table 27]

[0201] Preparation process: Step 1: Dissolve Phase A ingredients. Step 2: Heat Phase B ingredients until clear and cool to room temperature. Step 3: Once Phase B has cooled, add Phase C and gently shake to mix until a clear, almost transparent solution is formed. Then, add Phase BC to Phase A and stir until clear. Step 4: Add Phase D and shake gently to mix until a clear blue solution is formed.

[0202] Product 9 Oral spray containing 0.2% (w / w) of the composition of Example 14: [Table 28]

[0203] Preparation process: Step 1: Add ingredients to water and stir while gently heating (40-45°C). Step 2: Cool to room temperature while continuing to stir.

[0204] Product 10 A gel containing 0.2% (w / w) of the composition of Example 1 [Table 29]

[0205] Product 11 A natural deodorant containing 0.2% (w / w) of the composition of Example 5. [Table 30]

[0206] Preparation process: Step 1: Dissolve Phase A ingredients in water. Step 2: Dissolve the active ingredient and hexachlorophene in alcohol. Add flavoring and mix Phase B with Phase A.

[0207] Product 12 Antiperspirant blend containing 0.2% (w / w) of the composition of Example 1 [Table 31]

[0208] Preparation process: Step 1: Mix Phase A ingredients. Step 2: Add Phase A to the ingredients of Phase B to create Phase AB. Step 3: Dissolve the active ingredient and fragrance in the polysorbate. Step 4: Combine Phase AB with Phase C with stirring.

[0209] Product 13 Natural preservative blend for personal care products containing 0.2% (w / w) of the composition of Example 1 [Table 32]

[0210] Preparation process: Step 1 Disperse the composition of Example 1 in Polysorbate 20. Step 2 Add the xanthan gum. Step 3 Gradually add water and mix thoroughly.

[0211] All products 1 to 13 of the present invention were prepared according to the process described above and standard protocols for the manufacture of hygiene and cosmetic products.

[0212] Stability, Toxicity, and Biocidal Activity Tests Stability testing

[0213] Products 7, 8, and 9 Products 7, 8, and 9 were stored at different temperatures (5°C, 25°C, and 40°C) for 3 months, and physicochemical tests (appearance, color, odor, pH, and density) were performed periodically every 30 days. pH and density values were maintained over the 90-day period, with the pH varying by less than 5% and the density by less than 10% from the initial value.

[0214] During the test, concentrations of aerobic bacteria (ISO 21149:2017), molds, and yeasts (ISO 16212:2017) were less than 10 cfu / g, in accordance with ISO standards. Furthermore, Pseudomonas aeruginosa (ISO 22717:2016), Staphylococcus aureus (ISO 22718:2016), Escherichia coli (ISO 21150:2016), and Candida albicans (ISO 18416:2017) were completely undetectable even after 90 days.

[0215] From these results, it was concluded that the composition of the present invention is stable under the conditions of preparation, storage, and daily use, and has a shelf life of 36 months, since no degradation of the ingredients or loss of biocidal activity was observed.

[0216] Eye irritation test Products 7, 8, and 9 Eye irritation was measured using the HET-CAM technique. The effects of oral products 7, 8, and 9 were evaluated on the allantoic membrane (CAM) of fertilized eggs and observed for 5 minutes. After observation, the degree of hyperemia, bleeding, and clotting was scored on a scale of 0 to 9, with 0 indicating non-irritant and 9 indicating irritant. As a result of the eye irritation test, products 7 and 8 containing the composition of the present invention were confirmed to be non-irritating and received a score of 0.

[0217] Biobactericidal activity test Viral bactericidal activity test - Products 7 and 8Biocidal tests were performed according to the UNE-EN 14476 standard against the following viruses after a specific contact time: ECBO virus ATCC VR-37 (5 min), rotavirus ATCC CRL-2378.1 (15 min), vaccinia virus ATCC VR-1549 (5 min), polyomavirus SV40 ATCC pUCSV40-B2E (5 min), Lactobacillus bacteriophage ATCC 4356 (15 min), poliovirus ATCC VR-166 (15 min), adenovirus ATCC VR-1516 (5 min), and norovirus ATCC TIB-71 (5 min) under clean conditions.

[0218] Additionally, the following viruses were tested under contaminated conditions: hepatitis B virus ATCC VR-3232SD (5 min), coronavirus ATCC CCL-171 (5 min), herpesvirus ATCC CCL-81 (HSV) (5 min), and influenza A ATCC VR-95 (H7N9) (15 min). Product 3 was evaluated for its virucidal properties against HPV according to the UNE-EN 14476:2014 + A1 standard.

[0219] The results showed that all three concentrations of Product 3 met this criteria, requiring only 5 minutes of contact to inhibit HPV growth and reduce its viability.

[0220] Bactericidal activity test Products 7 and 8was tested according to the UNE-EN 1500:2013 standard for biocidal testing against bacteria at a fixed contact time. Specifically, Escherichia coli K12 ATCC 10536 was targeted under clean conditions (45 seconds), and the following bacteria were targeted under contaminated conditions: Candida albicans ATCC 10231 (5 minutes), Fusobacterium nucleatum ATCC 25586 (5 minutes), Porphyromonas gingivalis ATCC 53978 (5 minutes), Staphylococcus aureus ATCC 6538 (5 minutes), Lactobacillus casei ATCC 393 (5 minutes), Staphylococcus epidermis ATCC 12228 (5 minutes), and Streptococcus mutans ATCC 25175 (5 minutes).

[0221] Products 10-13 The products were evaluated for their antimicrobial properties under forced conditions against the pathogens disclosed in Section 4.1. All products were exposed to 41°C for 3 months and then analytically tested according to UNE-EN 14476:2014 + A1, UNE-EN 13697:2015, and UNE-EN 1500:2013 standards. Additionally, products 11 and 13 were analytically tested according to UNE-EN 1276:2010 and UNE-EN 1650:2008 standards to evaluate their activity and stability against the pathogens disclosed in Section 4.1. The test results confirmed that all test products, including the inventive compositions, demonstrated broad-spectrum, effective activity, eliminating all test pathogens even at low concentrations. In fact, all test products were effective in eliminating the most common pathogens under laboratory conditions. This efficacy was maintained even after exposure to extreme external conditions, indicating that the inventive compositions are stable even under extreme storage conditions. Furthermore, these compositions demonstrate high versatility for the manufacture of products in different formulations and administration routes, allowing their use without compromising the stability, safety, or bactericidal activity of the active ingredients.

[0222] D. Preservative / disinfectant activity Product 1 Product 1 was tested according to the UNE-EN 1500 standard for biocidal testing against bacteria, specifically against Escherichia coli K12 ATCC 10536 (45 seconds) under clean conditions.

[0223] Antiseptic products comprising the compositions of the present invention The aim of this study was to evaluate the preservative activity of the composition of the present invention in cosmetics or edible products (food / feed sector) in comparison with the most commonly used (and commercially available) cosmetic preservatives.

[0224] Preservatives tested Preservative 1: Product containing Ex. 1 of the present invention Comparative preservatives on the market: Comparative Preservative 1: KATHON CG (chloro-2-methyl-isothiazolin-3-6-one and 2-methyl-4-isothiazolin-3-one) Comparative preservative 2: ISCAGUARD PFA (caprylyl glycol, phenethyl alcohol) Comparative preservative 3: EUXYL K 701 (phenoxyethanol, benzoic acid, dehydroacetic acid, and ethylhexylglycerin) Comparative preservative 4: ISCAGUARD DGP (pentylene glycol, caprylyl glycol, and decylene glycol) Comparative preservative 5: ISCAGUARD PEG (phenoxyethanol, triethylene glycol) Comparative preservative 6: ISCAGUARD OP (phenoxyethanol, caprylyl glycol)

[0225] method The above commercial preservatives and the product of the present invention were tested against the most common bacteria, yeasts, and fungi at doses between 0.1% and 1.5% in a challenge test according to ISO 11930:2012.

[0226] result Table 6 shows the concentrations of the tested compositions that inhibit the growth of pathogens, expressed as % (w / w). [Table 33]

[0227] Additionally, the test preservatives of the present invention were tested against the following pathogens: Staphylococcus hominis ATCC 27845, Enterococcus hirae ATCC 10541, Streptococcus mutans ATCC 25175, Porphyromonas gingivalis ATCC 53978, Fusobacterium nucleatum ATCC 25586, Corynebacterium xerosis ATCC 7711, Micrococcus sp. ATCC 700405, Lactobacillus acidophilus ATCC 4356, Gardnerella vaginalis ATCC 14018, and Pityrosporum ovale ATCC 44341. Tests were conducted according to the standards UNE-EN 1500:2013 and UNE-EN 14476:2014+A1. The results showed that the composition of the present invention was effective against all tested pathogens, even at a low concentration of 0.1%.

[0228] In conclusion, the above results show that the composition of the present invention requires a much lower concentration to inhibit the growth of pathogens than other products, and furthermore, it is found to cover a wide range of pathogens. Therefore, it can be concluded that the composition of the present invention is a versatile and universal composition that can be used to prepare products for any purpose, regardless of the route of administration or formulation, without compromising efficacy, stability, or safety.

[0229] 8. Skin irritation clinical studies 8.1. Topical cream application The purpose of this clinical trial was to evaluate the skin irritation following application of a topical cream product (Product 14) containing petrolatum and 0.2% of the composition of Example 1 of the present invention. To accomplish this, 10 healthy subjects aged between 18 and 65 participated in the study. Five of the subjects had sensitive skin, and the remaining five had normal skin.

[0230] Product 14 was applied to the right hand only for three consecutive days. Each day, skin assessments were performed 30 minutes after application of Product 14, and dermatologists assessed the subjects for any irritation. No adverse reactions were reported by any of the subjects.

[0231] 8.2. Skin application test of patch The purpose of this clinical trial was to evaluate the skin irritation after applying a patch containing the composition of the present invention and to measure the skin irritation response, and 10 healthy volunteers aged 18 to 65 participated in the study.

[0232] As a method, 50 mm 2 20 μl of a product containing 0.2% (w / w) of the composition of the present invention was applied to a semi-occlusive hypoallergenic polypropylene patch made of nonwoven Curatest® fabric with an area of 100 μm and left on the skin for 48 hours. At the same time, a second patch without the test product was applied for comparison to control for any reaction caused by the patch itself.

[0233] After 48 hours, the patches were removed, and the experimental sites were evaluated 30 minutes later to check for any skin irritation caused by the patch. Additionally, 48 hours after patch removal, the subjects were re-evaluated to check for any delayed signs of irritation. The main signs of irritation (side effects) associated with the use of skin patches include erythema, edema, papules / vesicles / bulls / pustules, dryness / scaling, and a detergent effect (the appearance of wrinkles or an abraded appearance at the application site).

[0234] After 48 hours and 96 hours of applying the skin patch containing the composition of the present invention, no signs of irritation were observed.Therefore, it was confirmed that the product of the present invention has good compatibility with skin.From the results of both clinical trials, it can be concluded that the composition of the present invention and the product containing it have very good skin compatibility, and no signs of irritation or side effects were observed.

[0235] 9. Biofilm formation inhibition test The purpose of this study was to evaluate the biocidal activity of the compositions of the present invention as well as their ability to inhibit biofilm formation. Biofilms are complex matrices composed of extracellular polysaccharides, DNA, and proteins that protect bacteria from physical, chemical, and biological stresses, allowing them to survive in harsh environments. Biofilm formation involves three stages: cell attachment to a solid substrate, adhesion, and proliferation. Inhibiting any of these stages or targeting specific biofilm targets (e.g., proteins) can render pathogens defenseless against conventional antibiotics and prevent the development of bacterial resistance, while minimally affecting cell survival.

[0236] sample Sample 1: Contains 0.2% (w / w) of composition Ex.1 of the present invention Sample 2: Contains 1% (w / w) of the composition Ex.1 of the present invention Sample 3: Contains 2% (w / w) of composition Ex.1 of the present invention Sample 4: Composition Ex.1 of the present invention at 0.2% (w / w) + lactic acid at 0.1% Sample 5: Contains 2% (w / w) of composition Ex. 22 of the present invention Blank: No treatment

[0237] pathogenic bacteria Two strains of P. aeruginosa isolated from patients (PA14 and PA14M) Two laboratory strains of P. aeruginosa (PAO and PAOMUT) PA14M and PAOMUT are colistin-resistant strains. For purposes of the present invention, other P. aeruginosa strains may be used as well to demonstrate efficacy, such as P. aeruginosa ATCC 15442 and the colistin-resistant strain P. aeruginosa ATCC 27853.

[0238] method A single colony was inoculated into 10 ml of Luria-Batani (LB) broth and grown at 37°C for 16 hours with agitation. This culture was diluted with fresh Mueller-Hinton (MH) broth to a concentration of 10^6 CFU / ml. 100 μl of the resulting culture was then dispensed into a flat-bottom 96-well microtiter plate (Nunc TSP, System, Nunc, Roskilde, Denmark). The plate was covered with a lid containing 96 polystyrene projections on which biofilms could form. The system was incubated at 37°C for 48 hours under conditions favorable for biofilm formation.

[0239] The plates were incubated at 37°C for 24 h, and the protrusions were again washed three times and placed on another plate containing 100 μl of fresh MH broth per well. All devices were then centrifuged at 800 g for 10 min to allow the biofilm-attached protrusions to settle into the wells. After centrifugation (time point zero), the optical density (OD) of the culture medium was measured at a wavelength of 595 nm using a spectrophotometer (Flow Titertek Multiskan Plus, Flor Laboratorios, Finland). The culture was then incubated at 37°C for 6 hours, and the OD was measured again. The difference between the OD values at time zero and after 6 hours of incubation was calculated, and the minimum inhibitory concentration for biofilm (CMI-B) was defined as the initial concentration of the composition at which no growth was observed. Wells receiving medium alone served as negative controls for sterility and as positive controls for growth in the absence of compound.

[0240] After incubating the microtiter plates for 6 h, the optical density (OD) and CMI-Biofilm (CMI-B) values, which indicate growth within the biofilm, were measured.

[0241] result The biocidal effects of the test samples of the present invention against the above P. aeruginosa strains were measured after 15 and 30 minutes of exposure at 25°C and 37°C, compared to an untreated control. PA14 strain: A beneficial effect on biofilm formation was observed. PA14M, PAO, and PAOMUT strains: Biofilm growth inhibition of 96% to 100% was observed under all test conditions and for all test compositions of the present invention. The average biofilm growth inhibition rates (average of two replicates for each strain) against clinical strains of PA14M, PAO, and PAOMUT strains after 15 and 60 minutes of exposure at 25°C and 37°C, compared to an untreated control, are shown below: [Table 34]

[0242] Based on the above experimental data, it can be concluded that the compositions of the present invention have the ability to inhibit the formation and growth of biofilms. The compositions of the present invention are believed to be particularly advantageous because they have both a direct biocidal effect and an inhibitory effect on biofilm formation.

[0243] 10. Antibacterial Activity Test against Vegetative Cells of Clostridioides difficile Clostridioides difficile (C. difficile) is an anaerobic microorganism that is a major cause of antibiotic-associated diarrhea. This pathogen causes a spectrum of illnesses known as Clostridioides difficile infection (CDI), ranging from mild diarrhea to death. Transmission of this pathogen occurs primarily through spores in hospital settings and has been detected in patient rooms and on the gloves and uniforms of healthcare workers. To prevent the spread of infection within hospitals, patients with CDI must be isolated. Although vegetative C. difficile readily dies in the environment, it has the ability to produce spores, which can remain dormant for months to years until favorable conditions are met.

[0244] The purpose of this study is to evaluate the topical efficacy of compositions of the present invention in reducing the transmission of Clostridioides difficile.

[0245] Test sample Sample 1: containing 1% (w / w) of the composition of Example 22 of the present invention Sample 2: containing 2% (w / w) of the composition of Example 22 of the present invention Positive control (C2): 1% bleach Negative control (C1): Untreated Clostridioides difficile 027 / 078

[0246] Test pathogen Clostridioides difficile belonging to botypes 027 and 078 This study used ribotypes 027 and 078 of Clostridioides difficile (C. difficile) isolated from patients. Both strains were cultured on blood agar (BioMérieux®, Spain) and incubated at 37°C under anaerobic conditions for 24 hours. For the purposes of this study, other ribotypes of C. difficile may be used to demonstrate similar efficacy, such as C. difficile ATCC 9689.

[0247] method Colonies of Clostridioides difficile 027 and 078 grown on blood agar (BioMerieux®, Spain) were inoculated into 10 mL of brain heart infusion medium (Condolab®, Spain) and plated at a density of 3 on the McFarland scale (9 x 10 8 The cultures were grown until they reached a turbidity equivalent to 100 CFU / mL. These cultures were incubated at 37°C under anaerobic conditions for 8 hours, during which time the strains were in the exponential growth phase with low sporulation rates. The turbidity was then measured again using a McFarland nephelometer and adjusted to 3 with saline. Activity tests for Samples 1 and 2 (1% and 2%, respectively) were performed using a 96-well microtiter plate (Thermofisher®, Nunclon 96-Well MicroWell Plate with Lid, Flat; 50 / Cs, Denmark). To each well, 20 μL of cell suspension and 100 μL of Sample 1 or Sample 2 (1:6) were added. 100 μL of saline was added as a growth control, and 1% bleach (control) was also used as a bactericidal activity control.

[0248] The effects of the test samples were evaluated after 5, 15, and 30 minutes at room temperature and under anaerobic conditions. After the designated time, the plates were centrifuged at 2500 rpm for 15 minutes. The test samples were removed, and the cells deposited at the bottom of the wells were resuspended in 150 μL of brain heart infusion medium (BHI). The optical density (OD) of the wells was then measured at 600 nm (t = 0 h). The plates were then incubated at 37 °C under anaerobic conditions for 48 hours, after which the OD was measured again at 600 nm (t = 48 h). The effect of the test sample of the present invention on the trophozoites of ribotypes 027 and 078 of Clostridioides difficile was evaluated by the increase in OD600nm at 48 hours and 0 hours (DO600 / 48 - DO600 / 0). Statistical analysis of the results was performed using the Kruskal-Wallis test and Tukey's multiple comparison post-hoc test.

[0249] result The more effective the product, the smaller the increase in OD600 due to the reduction in the number of vegetative cells. In fact, if all C. difficile vegetative cells were killed, a negative value was detected. Using test samples 1 and 2 of the present invention and 1% bleach, the increase in OD600 of C. difficile was evaluated after 5, 15, and 30 minutes. Meanwhile, the OD600 of untreated C. difficile 027 / 078 (control) was also measured after 48 hours. The table below shows the efficacy of the tested compositions for both ribotypes of Clostridioides difficile as DO600 / 48 - DO600 / 0. [Table 35]

[0250] Untreated C. difficile 027 / 078 cultures were observed to increase in OD600 to approximately 0.1. In contrast, both compositions of the present invention (Samples 1 and 2) significantly reduced the percentage of C. difficile vegetative cells compared to untreated control cultures (p<0.001).

[0251] Both compositions (Samples 1 and 2) of the present invention significantly reduced the percentage of Clostridioides difficile vegetative cells compared to bleach treatment. In particular, Sample 2 (containing 2% of the composition of Example 22 of the present invention) was able to statistically reduce the activity of Clostridioides difficile 027 / 078 after only 5 minutes of exposure (p<0.05). Meanwhile, Sample 1 (containing 1% of the composition of Example 22 of the present invention) showed a statistically significant reduction after 15 minutes of exposure (p<0.05). Furthermore, as shown in the table above, negative DO600nm_t48h-DO600nm_t0h values were observed for the compositions of the present invention. In fact, these values were even more negative than those observed when bleach was used as a biocide. This means that the compositions of the present invention exhibit bactericidal efficacy against C. difficile vegetative cells comparable to that of bleach at short exposure times, and exhibit higher efficacy than bleach at longer exposure times of 15 minutes or more (see Figures 1 and 2).

[0252] Therefore, the compositions of the present invention are useful for preventing and / or treating diseases and conditions caused by Clostridioides difficile, and as disinfectants that do not cause surface (metal) corrosion, inorganic inactivation, or skin or mucosal irritation. Furthermore, the high efficiency of reducing Clostridioides difficile vegetative cells is also advantageous in terms of inhibiting stimulation of sporulation. Finally, the stability of the compositions of the present invention extends the product's shelf life, reducing the number of applications and potentially reducing the overall medical costs of treatment.

[0253] 11. Fungicidal activity test according to the UNE-EN 13697 standard The results for the compositions of Examples 1, 8, 18, 21 (listed in Tables 1 to 3) are as follows: Evaluation of fungicidal activity by internal method according to the UNE-EN 13697:2015 standard.

[0254] Conclusion: This product complies with UNE-EN 13697 (fungicidal) against the following fungi under contaminated conditions at a concentration of 0.2% in sterile water: Puccinia hordei ATCC 22604 Puccinia strifilis ATCC PR-53 Septoria tritica ATCC 26518 Puccinia recondita ATCC PR-67 Puccinia graminis ATCC PR-99 Podosphaera panosa Botrytis ATCC 11542 Phytophthora cinnamonii Ranz ATCC 46672 Pythium ATCC 24619 Pythiaceae ATCC 36433 Botryocephaleria corticola ATCC 60259 Dothideomycetes ATCC 6506 Ascomycota ATCC 18431 Theilariae ATCC 38988 Hypoxylon mediterraneanum ATCC 38992 Agrobacterium tumefaciens ATCC 53385 Rhizopus ATCC 20577 Fusarium oxysporum ATCC 62506 Peronospora tabacina ATCC 3904 Phytophthora nicotinadiae ATCC 38606 Erysiphe necator ATCC 55 608 (white powdery mildew) Podosphaera ATCC 46 674 (white powdery mildew) Plasmopara viticula ATCC 27 294 Erysiphe necator ATCC 55 608 (white powdery mildew) Podosphaera ATCC 46 674 (white powdery mildew) Plasmopara viticula ATCC 27 294 Verticillium ATCC 16535

[0255] 12 - Bactericidal activity test according to the UNE-EN 13697 standard The results for the compositions of Examples 1, 8, 18, and 21 (listed in Tables 1 to 3) are as follows: Evaluation of bactericidal activity by an internal method according to the UNE-EN 13697:2015 standard.

[0256] Conclusion: This product complies with UNE-EN 13697 (bactericidal) against the following bacteria under contaminated conditions at a concentration of 0.2% in sterile water: Pseudomonas sabastnoi ATCC 13522 Agrobacterium vitis ATCC 49767 Helicobacter pylori ATCC 700392

[0257] 13 - Antioxidant Activity Test The results for the compositions of Examples 1, 8, 18, and 21 disclosed in Tables 1-3 at a concentration of 100% (w / w) were as follows: Antioxidant activity testing was performed based on the ORAC (Oxygen Radical Absorbance Capacity) method, with a result of 1322 μmol Trolox equivalents / 100g.

[0258] In the ORAC method, a sample containing the substance being tested is prepared, and a free radical source, such as hydrogen peroxide (H2O2) or the free radical 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH), is added to the sample. The sample's ability to inhibit oxidation caused by free radicals is then measured. A fluorescent indicator, which emits light when oxidized, is used and placed in the presence of the sample and free radicals. As the sample scavenges free radicals, oxidation of the fluorescent indicator decreases, and so does the emission of light. Antioxidant activity is determined by measuring the decay of fluorescence over time. The greater the sample's free radical scavenging ability, the smaller the decay in fluorescence and the greater the antioxidant activity.

[0259] 14 - Bactericidal activity test under high pH conditions Tests of the bactericidal effect at high pH (pH 9) were carried out using samples with this pH. The results of the compositions of Examples 1, 8, 18, and 21 disclosed in Tables 1 to 3 and adjusted to pH 9 using 1% (w / w) sodium lauryl sulfate were as follows: Evaluation of bactericidal activity by internal test method according to standard UNE-EN 13697: 2015.

[0260] Conclusion: The product complies with the UNE-EN-13697 standard (disinfectants) as a disinfectant under soiled conditions at concentrations of 0.2% and 1% (w / w) sodium lauryl sulfate in sterile water with a contact time of 30 seconds. Common oral bacterial strains: Escherichia coli ATCC 10 536 Staphylococcus aureus ATCC 6538

[0261] 15 - Preservative Activity Test: Verification of the Optimal pH Range for Bacterial Growth The results for the compositions of Examples 1, 8, 18, and 21 disclosed in Tables 1-3 in sterile water at a concentration of 0.2% (w / w) were as follows: Cosmetic product bases were studied at pH 3.5 and pH 11.5 to assess the effectiveness of the products as preservatives. The pH 3.5 base (sample 1) was adjusted to pH 4.0 UpH using sodium bicarbonate. The pH 11.5 base (sample 2) was adjusted to pH 9.0 UpH using citric acid. Both samples were adjusted to the optimal pH range for microbial growth (pH 4.0-9.0 UpH) and then inoculated with aerobic microorganisms, molds, and yeast strains. A parallel positive control was also run to confirm the effectiveness of the inoculation. After 5 minutes, the microorganisms in the base sample and the positive control were confirmed. All analyses were performed according to the laboratory's internal procedures based on UNE-EN ISO standards and were carried out under a quality control system.

[0262] Conclusion: After evaluating the results of the controlled analysis, the product was confirmed to be effective as a preservative against microbial growth.

[0263] 16 - Antibacterial activity test based on US ASTM standards The results for the compositions of Examples 1, 8, 18, and 21 disclosed in Tables 1-3 at a concentration of 0.2% (w / w) in sterile water were as follows: The antibacterial activity of water-miscible substances was evaluated using an internal test method based on ASTM E2783-22 (American Society for Testing and Materials).

[0264] Conclusion: After 15 seconds of contact, the log reduction was 3.52 for Staphylococcus aureus ATCC 6538 and 3.49 for Escherichia coli ATCC 10536. Log reduction rate after 30 seconds of contact: A reduction of 6 or more was confirmed for both microorganisms.

[0265] 17 - Spray Efficiency Test The results for the compositions of Examples 1, 8, 18, and 21 disclosed in Tables 1-3 were as follows: The environmental and surface antimicrobial activity of spray application of the product at a concentration of 0.2% in sterile water is evaluated. After the first sampling, spraying of 0.2% product began. The dimensions of the test chamber were 4.20 m × 4.20 m × 2.95 m, and the spray equipment used was model KRDAP129-2B, with a spray flow rate of 70 ml / min, horizontal flow of 3 m, and spray particle size of 0–50 μM. Environmental and surface controls were performed sequentially after 5, 15, and 30 minutes. Sampling at each time point was performed according to the method described for the initial sampling (T=0). After the sampling process was completed, all samples were refrigerated for storage and transported to the laboratory. Testing for the target microorganisms is then carried out in the laboratory. Detection of the microorganisms is carried out according to the UNE-EN 13697:2015 standard by plating on selective media.

[0266] Conclusion: Based on the results of the test, it was concluded that when spray applied under the conditions described in the report, the 0.2% product exhibits antibacterial efficacy against the following microorganisms: Bacillus cereus count Coliform count Enterobacteriaceae number coli count Coagulase-positive staphylococci count Mold and yeast counts Total aerobic bacteria count at 30°C Total aerobic bacteria count at 37°C Mesophilic aerobic bacterial count Fecal streptococcus count Listeria monocytogenes Salmonella Enterohemorrhagic Escherichia coli (EHD) Brucella abortus Brucella melitensis Brucella Swiss anthrax Coxiella burnetii Echinococcus granulosus Leptospira canicola Leptospira icterohaemorrhagicus Leptospira pomona Chlamydia psittaci Streptococcus pyogenes Erysipelothrix rhusiopathiae Campylobacter spp. Proteus mirabilis Yersinia enterocolitica

[0267] 18 - Atomization Efficiency Test The results for the compositions of Examples 1, 8, 18, and 21 listed in Tables 1-3 were obtained at concentrations of 0.2% (w / w) plus 10.5% (w / w) glycerin, 27% (w / w) propylene glycol, and 61% (w / w) water as follows: The purpose of the tests described in the following sections was to determine the environmental and surface activity of FOGSANIX products applied as a mist against aerobic bacteria, anaerobic bacteria, E. coli, Listeria monocytogenes, mold, and yeast.

[0268] An initial inoculation of the target microorganisms was performed on the environment and surfaces. After inoculation, initial sampling was performed before starting the FOGSANIX product atomization process. Surface samples were taken with sterile cotton swabs, and environmental samples were taken using a SAS MicroBio Air Sampler MBI Plus (serial number: 01111302).

[0269] For surface sampling, moistened cotton swabs are used. The swabs are removed from their sterile packaging and the tip is moistened by dipping it into a tube containing diluent / neutralizing solution. The tip is pressed against the wall of the tube to remove excess diluent / neutralizing solution. The tip of the swab is placed on the surface at various heights (ground level, 1.50 m, 2.5 m, 4.5 m high), covering approximately 100 cm in each area. 2 The area is sampled vertically and horizontally, and the handle of the cotton swab is rotated between the thumb and index finger, scraping 10 times in each direction. The collected swabs are placed back into their respective tubes containing diluent / neutralizing solution, ensuring that the tubes are tightly closed to keep the swabs moist. For environmental sampling, the instrument is set to collect 200 liters in 2 minutes. After the exposure time is over, the plates are removed from the instrument and stored in the oven for incubation.

[0270] After the initial sampling, atomization of the FOGSANIX product begins using a 4Mediks atomization device (external dimensions: length 728 mm, width 428 mm, height 719 mm, voltage: AC 220-240, 50 / 60 Hz, 7 A). Atomization is performed on a total volume of 6,885 m3. 3 The test was conducted in an industrial facility (34m x 27m x 7.5m) with a spray time of 3 minutes 45 seconds and a maximum flow rate of 130ml / min. The total test consumption was 487ml. No water rinsing is required after application of the product.

[0271] Continuous environmental and surface control is performed after 5, 10, and 20 minutes. Sampling at different times is performed according to the sampling method described for the initial sampling (T=0).

[0272] After the sampling process is complete, the target microorganisms are tested in the laboratory. The analysis is carried out according to UNE-EN 13697: 2015 using the plating method on selective media.

[0273] Conclusion: FOGSANIX products applied as a mist under the conditions described in this report were found to be bactericidal against the microorganisms tested.

[0274] 19 - Barcelona Clinic Hospital Tests to establish MICs for Pseudomonas aeruginosa (ATCC 27853 and MB188) and Acinetobacter baumannii (ATCC 17978 and ATCC 19606) strains

[0275] The results for the compositions of Examples 1, 8, 18, and 21 listed in Tables 1-3 are as follows: The MICs (minimum inhibitory concentrations) of the products were determined against control strains of Pseudomonas aeruginosa and Acinetobacter baumannii under identical experimental conditions: exposure time 20-24 hours, temperature 37°C. The following two control strains were used as reference methods for MIC determination based on the microdilution method using 96-well microtiter plates: Pseudomonas aeruginosa (ATCC 27853 and MB188) Acinetobacter baumannii (ATCC 17978 and ATCC 19606)

[0276] The medium chosen for testing was Mueller Hinton II Broth (CAMH) with cation adjustments for calcium and magnesium ions, which is commonly used for susceptibility testing of aerobic gram-negative and gram-positive bacteria. Considering that the approved biocide concentration is 0.2% (2000 μg / ml), the test concentration range was selected to be 65,536 μg / ml to 128 μg / ml.

[0277] Additional testing: To confirm the effectiveness of Tween 20 in the biocide solution, tests were conducted with the biocide compound and Tween 20 (at twice the concentration of the biocide compound). First, the 0.5 McFarland standard (1.5 × 10) of each strain was used.8 CFU / ml) and a 1 / 1000 dilution was performed in CAMH medium, resulting in an initial inoculum concentration on the plate of approximately 1.5 × 10 5 CFU / ml. For the microtiter plate assay, 50 μg of CAMH medium was added to each well, followed by serial dilutions of 50 μg of each control strain at the maximum concentration (65,536 μg / ml for biocide compounds and 131,072 μg / ml for Tween 20). The minimum concentrations were 128 μg / ml for biocide compounds and 256 μg / ml for Tween 20. Then, 1.5 × 10 5 50 μg of each strain was inoculated at a concentration of CFU / ml, and the plates were incubated at 37°C overnight. After incubation, each plate was read and the formation of a button on the bottom of the well confirmed bacterial growth as a positive result. [Table 36]

[0278] Conclusion: With the strains used and under the test conditions, the product showed antibacterial activity at concentrations below 2,000 μg / ml.

[0279] 20 - Bactericidal Activity Test The results for the composition of Example 22 listed in Table 3 are as follows: Test results at a concentration of 0.2% (w / w) in sterile water. Bactericidal activity evaluation by internal method according to UNE-EN 13697: 2015. Conclusion: The product complies with the UNE-EN-13697 standard (bactericidal effect) under contaminated conditions and is 100% effective against the following bacteria at a concentration of 95% with a contact time of 5 minutes: Pseudomonas aeruginosa ATCC 15 442 Escherichia coli ATCC 10 536 Staphylococcus aureus ATCC 6538 Enterococcus hirae ATCC 10 541

[0280] 21 - Fungicidal Activity Test The results for the composition of Example 22 listed in Table 3 are as follows: Test results at concentrations of 0.2% and 0.19% (w / w) in sterile water. Fungal activity evaluation by internal method according to UNE-EN 13697: 2015.

[0281] The product complies with the UNE-EN-13697 standard (fungal effectiveness) under contaminated conditions and is effective against the following fungi at concentrations of 0.2% and 0.19% with a contact time of 5 minutes: Candida albicans ATCC 10231 Aspergillus brasiliensis ATCC 16404

[0282] 22 - Antioxidant Activity Test The results of the composition of Example 22 listed in Table 3 are as follows: At a concentration of 100% (w / w), the antioxidant activity test was carried out based on the ORAC (Oxygen Radical Absorbance Capacity) method, and the result was 1251 μmol Trolox equivalents / 100g.

[0283] These results show that the compositions of the present invention achieve very high biocidal activity despite the low concentration of active ingredient. Furthermore, it is important to note that these products have low toxicity and can be registered under the simplified approval procedure under EU Regulation No. 528 / 2012.

[0284] The simplified authorisation procedure (EU Regulation No 528 / 2012) aims to promote the use of biocidal products that have less adverse effects on the environment and on human and animal health. For a biocidal product to be eligible for the simplified authorisation procedure, it must fulfil all of the following conditions: Biocidal products do not contain substances of concern Biocidal products do not contain nanomaterials The biocidal product has sufficient efficacy The handling and use of biocidal products does not require the use of personal protective equipment.

[0285] The composition of the present invention achieves a minimum inhibitory concentration (MIC) of up to 0.2% against all tested pathogens due to the synergistic effect between the different substances, which allows it to be registered as a non-harmful and non-toxic biocidal product according to ECHA regulations (see: ECHA Regulation: Simplified Approval of Biocidal Products). This effect cannot be achieved with the individual components or with combinations outside the scope of the present invention.

[0286] Terms For completeness, each aspect of the invention is described in the following numbered clauses.

[0287] Article 1. A composition comprising: 5-isopropyl-2-methylphenol or extracts containing it, weight percentage 0.1% to 45%; 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane or extracts containing it, weight percentage 0.1% to 45%; 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol or extracts containing it, weight percentage 0.1% to 60%; 5-methyl-2-(propan-2-yl)phenol or extracts containing it, weight percentage 0.1% to 45%; 5-methyl-2-(propan-2-yl)cyclohexan-1-ol or extracts containing it, weight percentage 0.1% to 45%; If desired, it may contain one or more additional active ingredients. Where appropriate, it may contain one or more suitable acceptable excipients or carriers.

[0288] Clause 2. A composition as defined in clause 1, comprising: 5-isopropyl-2-methylphenol or extracts containing it, weight percentage 0.5% to 45%; 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane or extracts containing it, weight percentage 0.5% to 42%; (c) 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol or an extract containing it, weight percentage 10% to 57%; 5-methyl-2-(propan-2-yl)phenol or extracts containing it, weight percentage 1% to 42%; 5-methyl-2-(propan-2-yl)cyclohexan-1-ol or extracts containing it, weight percentage 0.5% to 40%; If desired, it may contain one or more additional active ingredients. Where appropriate, it may contain one or more suitable acceptable excipients or carriers.

[0289] especially, (a) 5-isopropyl-2-methylphenol or an extract containing it in a weight ratio of 1% to 43%; (b) 1,3,3-trimethyl-2-oxabichloro[2.2.2]octane or an extract containing it in a weight ratio of 1% to 40%; (c) 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol or an extract containing it in a weight ratio of 15% to 55%; (d) 5-methyl-2-(propan-2-yl)phenol or an extract containing it in a weight ratio of 1% to 40%; (e) 5-methyl-2-(propan-2-yl)cyclohexan-1-ol or an extract containing it in a weight ratio of 0.5% to 35%; (f) May contain one or more additional active ingredients, if desired. (g) It may contain one or more suitable and acceptable excipients or carriers, as required.

[0290] Clause 3. A composition according to any one of clauses 1-2, comprising: 5-isopropyl-2-methylphenol or extracts containing it, weight percentage 2% to 43%; 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane or extracts containing it, weight percentage 2% to 35%; 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol or extracts containing it, weight percentage 17% to 54%; 5-methyl-2-(propan-2-yl)phenol or extracts containing it, weight percentage 1.5% to 38%; 5-methyl-2-(propan-2-yl)cyclohexan-1-ol or extracts containing it, weight percentage 1% to 30%; If desired, it may contain one or more additional active ingredients. Where appropriate, it may contain one or more suitable acceptable excipients or carriers.

[0291] especially: 5-Isopropyl-2-methylphenol, weight percentage 3% to 43%; 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, weight percentage 3% to 32%; 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol, weight percentage 20% to 53%; 5-methyl-2-(propan-2-yl)phenol, weight percentage 2% to 33%; 5-methyl-2-(propan-2-yl)cyclohexan-1-ol, weight percentage 1.5% to 20%; If desired, it may contain one or more additional active ingredients. Where appropriate, it may contain one or more suitable acceptable excipients or carriers.

[0292] Clause 4. The composition of any of clauses 1-3, wherein the one or more additional active ingredients are selected from the group consisting of antibiotics, antivirals, antifungals, antiyeasts, disinfectants, skin conditioning agents, and prebiotics.

[0293] Clause 5. The composition of claim 4, wherein the one or more additional active ingredients are selected from organic acid-containing compounds, quaternary ammonium-containing compounds, methyl N-methylanthranilate or an extract containing same, guaiacol or an extract containing same, p-cresol or an extract containing same, cinnamaldehyde, geraniol, citral, methyl dihydrojasmonate (hedione), 3-(propan-2-ylphenyl)butanal (florhydral), cis-para-menthanol (cyclohexanemethanol, 4-(1-methylethyl)-, cis-), and delta-damascone.

[0294] In particular, they are selected from lactic acid, citric acid, hyaluronic acid, pyruvic acid, ferulic acid, benzalkonium chloride, dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride, methyl N-methylanthranilate or an extract containing it, guaiacol or an extract containing it, p-cresol or an extract containing it, cinnamaldehyde, geraniol, and citral.

[0295] Clause 6. Composition according to any of claims 1 to 5, wherein the additional active ingredient consists of: a mixture of benzalkonium chloride and dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride; in particular from 5% to 20% by weight. or A mixture of methyl N-methylanthranilate, guaiacol, and p-cresol; in particular, 0.1% to 25% by weight of methyl N-methylanthranilate, 0.1% to 25% by weight of guaiacol, and 0.1% to 25% by weight of p-cresol. or One or more selected from cinnamaldehyde, geraniol, citral; especially 5% to 20% by weight.

[0296] Clause 7. A composition according to any one of claims 1 to 6, wherein one or more suitable and acceptable excipients or carriers are selected from surfactants, pH adjusters, gelling agents, solvents, co-solvents, rheology modifiers, preservatives, antioxidants, pH adjusters, emulsifiers, stabilizers, chelating agents, fragrances, and perfumes.

[0297] Clause 8. A composition according to any one of claims 1 to 7, wherein the pH is 8 or less; or the pH is greater than 8.

[0298] Article 9. Products containing: (i) an effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more suitable and acceptable excipients or carriers;

[0299] Clause 10. Product according to claim 9, containing a composition as defined in any one of claims 1 to 8 in a weight ratio of 0.001% to 10% relative to the total weight of the product; in particular in a weight ratio of 0.001% to 7%; in particular 0.001% to 5% by weight; in particular 0.001% to 4% by weight; in particular 0.001% to 3% by weight; in particular 0.01% to 3% by weight; Particularly including 0.1% to 3% by weight; particularly 0.2% to 3% by weight; and particularly 0.01% to 2% by weight.

[0300] Clause 11. A composition as defined in any one of claims 1 to 8; or a product as defined in any one of claims 9 and 10, selected from the group consisting of: A pharmaceutical composition or product comprising: (i) a therapeutically effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more pharmaceutically acceptable excipients or carriers; A veterinary composition or product comprising: (i) a veterinarily effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more veterinarily acceptable excipients or carriers; A cosmetic composition or product comprising: (i) a cosmetically effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more cosmetically acceptable excipients or carriers; A plant protection composition or product comprising: (i) a plant protection-effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more agriculturally acceptable excipients or carriers; A disinfecting composition or product comprising: (i) a disinfecting-effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more suitable and acceptable excipients or carriers; A dietary supplement composition or product comprising: (i) an effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more edibly acceptable excipients or carriers; A food / feed additive composition or product comprising: (i) an effective amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more edibly acceptable excipients or carriers; A fragrance / perfume composition or product comprising (i) a suitable amount of a composition as defined in any one of claims 1 to 8; and (ii) one or more suitable excipients or carriers. Clause 12. A product as defined in any one of claims 9 to 11, which is a therapeutic medicinal product or an animal product for veterinary use. In particular, for use as a biofungicide.

[0301] For use in the treatment or prevention of bacterial, viral, fungal or yeast diseases or conditions, in particular those caused by pathogens belonging to the following groups: VPH (human papillomavirus), HBV (hepatitis B virus), coronavirus, herpesvirus, H7N9 (influenza A), ECBO (bovine enterovirus), rotavirus (viral colitis), vaccinia virus (smallpox), polyomavirus SV40, lactobacillus bacteriophage, poliovirus, adenovirus, norovirus (viral colitis), Epstein-Barr virus, poliovirus type 1, LSc-2ab (picornavirus), adenovirus type 5, strain Adenoid 75, ATCC VR-5, Murine Norovirus, strain S99 Berlin, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus epidermidis, Enterococcus hirae, Burkholderia cepacia, Streptococcus mutans, Porphyromonas gingivalis, Fusobacterium nucleatum, Corynebacterium xerosis, Mycococcus spp., Lactobacillus acidophilus Rus, Gardnerella bagionalis, Propionibacterium acnes, Legionella pneumophila, Proteus var. virulence, Salmonella (Enteritis), Listeria monocytogenes, fungal spores (Teliospore, Zoospore, Ascospore, Zygospore), Bacillus, Clostridia, Xylella fastidiosa, Clostridium difficile, Arvinia amylovora, Xanthomonas arboricola pv.Pruni, Candida albicans, Aspergillus brasiliensis, Aspergillus niger, Pityrosporum ovale, Campylobacter, Botrytis cinerea, Fusorium, Mildew, Oidio, Phytospora, Pythium, Fusorium oxysporum, Peronospora tabacina (tobacco), Phytospora nicotinadiae (tobacco), Puccinia hordii, Puccinia striiformis, Septoria triti Ki, Puccinia recondita, Puccinia graminis, Puccinia striiviformis, Phytospora cinnamonilans, Pythium speculum, Pythium sterrum, Pythiumiaceae, Botryosseria corticola, Dotydiomycete fungi, Ascomycete fungi, Xanthalales, Visconia mediterranea, Agrobacterium tumefaciens, Pseudomonas savustanoi, Agrobacterium vitis.

[0302] Clause 13. Use of a product according to any one of claims 9 to 11 in a cosmetic product as a cosmetic, in particular as a skin care agent, more particularly where the skin care comprises improving at least one of the following symptoms: roughness, peeling, dryness, tightness, cracking, lack of elasticity, in particular as a deodorant, and in particular as an antioxidant and / or preservative.

[0303] Clause 14. Use of a product according to any of claims 9 to 11 as a plant protection biofungicide or booster agent for plant protection. In particular for use in the treatment or prevention of bacterial, viral, fungal or yeast diseases or conditions in plants, more particularly for use in the treatment or prevention of diseases or conditions in plants. More specifically against plants and fruit trees caused by pathogens selected from fire blight, bacterial spot of stone fruit trees and almond trees. Clause 15. Use of a product according to any one of claims 9 to 11, For use as a disinfectant for solid surfaces, spaces, and water, especially as a disinfectant product. or Use as a food / feed additive product, especially as a food / feed preservative, antioxidant, antiseptic and biocide, as well as a technical aid.

[0304] Citation List cf. Halldor Thormar, Lipids and Essential Oils as Antimicrobial Agents, Wiley Ed, edition 2011, chapter 9- 11, pp. 203-262). EP0244363 European Standard Protocol UNE-EN 1276: 2010 European Standard Protocol UNE-EN-13697:2015 European Standard Protocol UNE-EN 14476: 2014 + A1 European Standard Protocol UNE-EN 1650: 2008 + A1 European Standard Protocol UNE-EN 1500: 2013 European Standard Protocol UNE-EN 1650:2008 European Standard Protocol UNE-EN 14476 ISO StandardISO 16212:2017 ISO StandardISO 22717:2016 ISO StandardISO 22718:2016 ISO StandardISO 21150:2016 ISO StandardISO 18416:2017 ISO StandardISO 21149:2017 American Society for Testing and Materials ASTM E2783-22 1 European Standard Protocol UNE-EN 1276:2020 EU Regulation No 528 / 2012 https: / / echa.europa.eu / es / regulations / biocidal-products-regulation / authorisation-of-biocidal- products / simplified-authorisation

Claims

1. Composition: (a) containing 25% to 43% by weight of 5-isopropyl-2-methylphenol (carvacrol); (b) containing 20% to 38% by weight of 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol); (c) 21% to 38% by weight of 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol); the sum of the ingredients adds up to 100% by weight.

2. The composition of claim 1, further comprising 1% to 9% by weight of 5-methyl-2-(propan-2-yl)phenol (thymol).

3. 3. The composition according to claim 1, further comprising 1% to 9% by weight of 5-methyl-2-(propan-2-yl)cyclohexan-1-ol (menthol).

4. 4. The composition of any one of claims 1 to 3, further comprising one or more additional active ingredients.

5. The composition of any preceding claim, wherein the one or more additional active ingredients are selected from the group consisting of antibiotics, antivirals, antifungals, antiyeasts, disinfectants, skin conditioning agents, and prebiotics.

6. The composition of claim 5, wherein the one or more additional active ingredients are selected from the group consisting of organic acid-containing compounds, quaternary ammonium-containing compounds (such as quaternary ammonium silane salts), methyl n-methylanthranilate, guaiacol, p-cresol, cinnamaldehyde, geraniol, citral, methyl dihydrojasmonate (hedione), 3-(3-propan-2-ylphenyl)butanal (fluoridolol), cis-para-menthanol (cyclohexanemethanol, 4-(1-methylethyl)-, cis-), delta-damascone, eugenol, p-cymene, α-pinene, β-pinene, β-caryophyllene, caryophyllene oxide, terpinene, and terpinolene. In particular, selected from the group consisting of lactic acid, citric acid, hyaluronic acid, pyruvic acid, ferulic acid, benzalkonium chloride, dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride, methyl n-methylanthranilate, guaiacol, p-cresol, cinnamaldehyde, geraniol, and citral.

7. A composition according to any one of claims 4 to 6, wherein the additional active ingredient is one of the following: a mixture of benzalkonium chloride and dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride; in particular 5 to 20% by weight. or A mixture of methyl n-methylanthranilate, guaiacol, and p-cresol; in particular, 0.1% to 25% by weight of methyl n-methylanthranilate, 0.1% to 25% by weight of guaiacol, and 0.1% to 25% by weight of p-cresol. or One or more selected from the group consisting of cinnamaldehyde, geraniol, citral; in particular 5% to 20% by weight.

8. 8. The composition of any one of claims 1-7, further comprising one or more suitable acceptable excipients or carriers.

9. The composition of claim 8, wherein one or more suitable acceptable excipients or carriers are selected from the following group: surfactants, pH adjusters, gelling agents, solvents, co-solvents, rheology modifiers, preservatives, antioxidants, pH adjusters, emulsifiers, stabilizers, chelating agents, flavors, fragrances, and perfumes.

10. A composition comprising the components described in any one of claims 1-9.

11. A composition according to any one of claims 1 to 10, a concentration of carvacrol of 30% to 40% by weight; a eucalyptol concentration of 25% to 36% by weight; a terpinen-4-ol concentration of 25% to 36% by weight; If thymol is present, its concentration is between 1% and 6% by weight; If menthol is present, its concentration should be between 2% and 5% by weight.

12. 12. The composition of claim 11, (a) a concentration of carvacrol of 30% to 35% by weight; a eucalyptol concentration of 31% to 36% by weight; The concentration of terpinen-4-ol is 31% to 36% by weight.

13. 12. The composition of claim 11, a concentration of carvacrol of 35% to 40% by weight; a eucalyptol concentration of 25% to 30% by weight; a terpinen-4-ol concentration of 25% to 30% by weight; If thymol is present, its concentration is between 3% and 6% by weight; If menthol is present, its concentration should be between 2% and 5% by weight.

14. A product comprising: from 0.001% to 50% by weight of the composition as defined in any of the preceding claims, in particular from 0.01% to 2% by weight of the total product.

1. A composition as defined in any preceding claim, more particularly comprising a composition as defined in any preceding claim in an amount of from 0.01% to 0.5% by weight relative to the total weight of the product; Containing one or more suitable acceptable excipients or carriers.

15. The present invention relates to a composition as defined in claims 1-13 or a product as defined in claim 14, selected from the following group: A pharmaceutical composition or product comprising: (i) a therapeutically effective amount of a composition as defined in claims 1-13; and (ii) one or more pharmaceutically acceptable excipients or carriers. A veterinary composition or product comprising: (i) an animal therapeutically effective amount of a composition as defined in claims 1-13; and (ii) one or more animal-acceptable excipients or carriers. A cosmetic composition or product comprising: (i) a cosmetically effective amount of the composition defined in claims 1-13; and (ii) one or more cosmetically acceptable excipients or carriers. A plant protection composition or product comprising: (i) a plant protection effective amount of a composition as defined in claims 1-13; and (ii) one or more agriculturally acceptable excipients or carriers. A disinfecting composition or product comprising: (i) a disinfectant-effective amount of the composition defined in claims 1-13; and (ii) one or more suitable and acceptable excipients or carriers. A nutritional supplement composition or product comprising: (i) an effective amount of a composition as defined in claims 1-13; and (ii) one or more edibly acceptable excipients or carriers. A food / feed additive composition or product comprising: (i) an effective amount of a composition as defined in claims 1-13; and (ii) one or more edibly acceptable excipients or carriers. A fragrance / perfume composition or product comprising: (i) a suitable amount of the composition defined in claims 1-13; and (ii) one or more suitable excipients or carriers. Includes:

16. A method for producing a product according to any one of claims 14-15, comprising mixing a composition as defined in any one of claims 1-13 with one or more suitable acceptable excipients or carriers.

17. A product according to any one of claims 14-15, which is a medicinal product for use in therapy or a veterinary product for use in veterinary medicine, in particular for use as a fungicide, In particular, for use in the treatment or prevention of bacterial, viral, fungal, or yeast diseases or conditions, In particular, for use in the treatment or prevention of bacterial, viral, fungal, or yeast diseases or conditions caused by pathogens selected from the group consisting of: VPH (Human Papillomavirus), HBV (Hepatitis B Virus), Coronavirus, Herpesvirus, H7N9 (Influenza A), ECBO (Bovine Enterovirus B), Rotavirus (Viral Colitis), Vaccinia Virus (Smallpox), Polyomavirus SV40, Bacteriophage for Lactobacillus, Poliovirus, Adenovirus, Norovirus (Viral Colitis), Epstein-Barr Virus, Poliovirus Type 1, LSc-2ab (Picornavirus), Adenovirus Type 5, Strain Adenoid 75, ATCC VR-5, Murine Norovirus, strain S99 Berlin, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus hirae, Barkholzia cepacia, Streptococcus mutans, Porphyromonas gingivalis, Fusbacterium nucleatum, Corynebacterium serovar cerevisiae, Micrococcus spp., Lactobacillus acidophilus, Gardnera vaginalis, Propionibacterium aeruginosa Ness, Legionella pneumophila, Proteus vulgaris, Salmonella (Enteritis), Listeria monocytogenes, fungal spores (Theriospores, Zoospores, Ascospores, Zygospores), Bacillus, Clostridia, Xerella fastidiosa, Clostridium difficile, Erwinia amylovora, Xanthomonas alboricola pv. prunii, Candida albicans, Aspergillus brasiliensis Riensis, Aspergillus niger, Pityrosporum ovale, Campylobacter, Botrytis cinerea, Fusarium, Mildew, Oidio, Phytohotta, Pythium, Fusarium oxysporum, Peronospora tabacina (tobacco), Phytohotta nicotinadie (tobacco), Puccinia hordii, Puccinia striaformis, Septoria triti, Puccinia recondita, Puccinia graminis, Puccinia striaformis, Phytohotta cinnamonilans, Pythium speculum, Pythium sterillum, Pythium uiphace, Botryosphaeria corticola, Dotidiomycete fungi, Ascomycete fungi, Xanthalales, Visconia mediterranea, Agrobacterium tumefaciens, Pseudomonas savastanoi, Agrobacterium vitis.

18. 16. A product according to any one of claims 14-15 for use as a cosmetic; in particular as a skin care agent; more particularly as a skin care agent which improves at least one of the following symptoms: roughness, peeling, dryness, tightness, cracking, loss of elasticity; in particular as a deodorant; in particular as an antioxidant and / or preservative.

19. Use of a product according to any one of claims 14-15 as a biocide or booster agent for plant protection. In particular, for use in treating or preventing bacterial, viral, fungal, or yeast plant diseases or conditions. More particularly for use in treating plant diseases or conditions. More particularly for use on plants and fruit trees which are affected by pathogens selected from those which cause fire blight, bacterial spot of fruit trees and almonds. A product according to any of claims 14-15: as a disinfectant product, in particular as a disinfectant for solid surfaces, spaces and water; or alternatively as a food / feed additive product, in particular as a food / feed preservative, food / feed antioxidant, food / feed antiseptic and food / feed biocide, and as a technical aid.

Images